Patterson Companies (PDCO) 10-K 29 Jun 22 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Apr. 30, 2022	Jun. 21, 2022	Oct. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Apr. 30, 2022
Current Fiscal Year End Date	--04-30
Document Transition Report	false
Entity File Number	0-20572
Entity Registrant Name	PATTERSON COMPANIES, INC.
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-0886515
Entity Address, Address Line One	1031 Mendota Heights Road
Entity Address, City or Town	St. Paul
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55120
City Area Code	651
Local Phone Number	686-1600
Title of 12(b) Security	Common Stock, par value $.01
Trading Symbol	PDCO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 3,016
Entity Common Stock, Shares Outstanding		96,740,000
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0000891024

Audit Information

Audit Information	12 Months Ended
	Apr. 30, 2022
Auditor Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Minneapolis, Minnesota
Auditor Firm ID	42

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Current assets:
Cash and cash equivalents	$ 142,014	$ 143,244
Receivables, net of allowance for doubtful accounts of $5,913 and $6,138	447,162	449,235
Inventory	785,604	736,778
Prepaid expenses and other current assets	304,242	286,672
Total current assets	1,679,022	1,615,929
Property and equipment, net	213,140	219,438
Operating lease right-of-use assets, net	70,722	77,217
Long-term receivables, net	138,812	223,970
Goodwill, net	140,630	139,932
Identifiable intangibles, net	252,614	279,644
Investments	139,182	105,522
Other non-current assets, net	107,508	89,859
Total assets	2,741,630	2,751,511
Current liabilities:
Accounts payable	681,321	609,264
Accrued payroll expense	102,266	118,425
Other accrued liabilities	173,734	175,975
Operating lease liabilities	29,348	32,252
Current maturities of long-term debt	0	100,750
Borrowings on revolving credit	29,000	53,000
Total current liabilities	1,015,669	1,089,666
Long-term debt	488,554	487,545
Non-current operating lease liabilities	43,332	48,318
Deferred income taxes	120,414	124,491
Other non-current liabilities	31,026	36,820
Total liabilities	1,698,995	1,786,840
Stockholders’ equity:
Common stock	968	968
Additional paid-in capital	200,520	169,099
Accumulated other comprehensive loss	(81,516)	(62,592)
Retained earnings	921,704	855,741
Total stockholders’ equity	1,041,676	963,216
Noncontrolling interests	959	1,455
Total stockholders’ equity	1,042,635	964,671
Total liabilities and stockholders’ equity	$ 2,741,630	$ 2,751,511

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Statement of Financial Position [Abstract]
Receivables, allowance for doubtful accounts	$ 5,913	$ 6,138
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	600,000	600,000
Common stock, issued shares (in shares)	96,762	96,813
Common stock, outstanding shares (in shares)	96,762	96,813

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME - USD ($) shares in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Income Statement [Abstract]
Net sales	$ 6,499,405,000	$ 5,912,066,000	$ 5,490,011,000
Cost of sales	5,210,318,000	4,708,936,000	4,292,601,000
Gross profit	1,289,087,000	1,203,130,000	1,197,410,000
Operating expenses	1,132,085,000	992,523,000	1,094,474,000
Goodwill impairment	0	0	675,055,000
Operating income (loss)	157,002,000	210,607,000	(572,119,000)
Gains on investments	101,809,000	0	34,334,000
Other income (expense):
Other income (expense), net	27,731,000	13,608,000	(10,835,000)
Interest expense	(20,288,000)	(24,284,000)	(41,787,000)
Income (loss) before taxes	266,254,000	199,931,000	(590,407,000)
Income tax expense (benefit)	64,540,000	44,822,000	(1,040,000)
Net income (loss)	201,714,000	155,109,000	(589,367,000)
Net loss attributable to noncontrolling interests	(1,496,000)	(872,000)	(921,000)
Net income (loss) attributable to Patterson Companies, Inc.	$ 203,210,000	$ 155,981,000	$ (588,446,000)
Earnings (loss) per share attributable to Patterson Companies, Inc.:
Basic (in usd per share)	$ 2.09	$ 1.63	$ (6.25)
Diluted (in usd per share)	$ 2.06	$ 1.61	$ (6.25)
Weighted average shares:
Basic (in shares)	97,277	95,599	94,154
Diluted (in shares)	98,514	96,664	94,154
Dividends declared per common share (in usd per share)	$ 1.04	$ 1.04	$ 1.04
Comprehensive income (loss)
Net income (loss)	$ 201,714,000	$ 155,109,000	$ (589,367,000)
Foreign currency translation gain (loss)	(19,966,000)	33,405,000	(14,062,000)
Cash flow hedges, net of tax	1,042,000	1,042,000	7,999,000
Comprehensive income (loss)	$ 182,790,000	$ 189,556,000	$ (595,430,000)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Unearned ESOP Shares	Non-controlling interests
Beginning balance at Apr. 27, 2019	$ 1,480,507	$ 1,447	$ 953	$ 131,460	$ (88,269)	$ 1,483,496	$ 1,447	$ (50,381)	$ 3,248
Beginning balance (in shares) at Apr. 27, 2019			95,272
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation	(14,062)				(14,062)
Cash flow hedges	7,999				7,999
Net income (loss)	(589,367)					(588,446)			(921)
Dividends declared	(99,552)					(99,552)
Common stock issued and related tax benefits	(7,784)		$ 6	(7,790)
Common stock issued and related tax benefits (in shares)			675
Stock based compensation	22,936			22,936
ESOP activity	34,320							34,320
Adoption of ASU 2018-02	0				(2,707)	2,707
Ending balance at Apr. 25, 2020	836,444		$ 959	146,606	(97,039)	799,652		(16,061)	2,327
Ending balance (in shares) at Apr. 25, 2020			95,947
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation	33,405				33,405
Cash flow hedges	1,042				1,042
Net income (loss)	155,109					155,981			(872)
Dividends declared	(99,892)					(99,892)
Common stock issued and related tax benefits	1,279		$ 9	1,270
Common stock issued and related tax benefits (in shares)			866
Stock based compensation	21,223			21,223
ESOP activity	16,061							16,061
Ending balance at Apr. 24, 2021	$ 964,671		$ 968	169,099	(62,592)	855,741		0	1,455
Ending balance (in shares) at Apr. 24, 2021	96,813		96,813
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation	$ (19,966)				(19,966)
Cash flow hedges	1,042				1,042
Net income (loss)	201,714					203,210			(1,496)
Dividends declared	(102,257)					(102,257)
Common stock issued and related tax benefits	7,626		$ 10	7,616
Common stock issued and related tax benefits (in shares)			981
Repurchases of common stock	(35,000)		$ (10)			(34,990)
Repurchases of common stock (in shares)			(1,032)
Stock based compensation	23,805			23,805
Contribution from noncontrolling interest	1,000								1,000
Ending balance at Apr. 30, 2022	$ 1,042,635		$ 968	$ 200,520	$ (81,516)	$ 921,704		$ 0	$ 959
Ending balance (in shares) at Apr. 30, 2022	96,762		96,762

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Operating activities:
Net income (loss)	$ 201,714,000	$ 155,109,000	$ (589,367,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	44,180,000	41,669,000	44,981,000
Amortization	37,812,000	37,227,000	37,201,000
Gains on investments	(101,809,000)	0	(34,334,000)
Goodwill impairment	0	0	675,055,000
Bad debt expense	2,769,000	2,559,000	2,008,000
Non-cash employee compensation	23,805,000	30,488,000	37,354,000
Accelerated amortization of debt issuance costs on early retirement of debt	0	0	8,984,000
Deferred income taxes	(4,718,000)	(10,760,000)	(31,800,000)
Non-cash (gains) losses and other, net	(1,431,000)	1,318,000	0
Change in assets and liabilities:
Receivables	(1,144,833,000)	(916,694,000)	(540,065,000)
Inventory	(53,871,000)	91,193,000	(59,258,000)
Accounts payable	80,904,000	(268,338,000)	219,613,000
Accrued liabilities	(27,630,000)	85,849,000	25,474,000
Other changes from operating activities, net	(37,886,000)	19,861,000	(39,390,000)
Net cash used in operating activities	(980,994,000)	(730,519,000)	(243,544,000)
Investing activities:
Additions to property and equipment	(38,308,000)	(25,788,000)	(41,809,000)
Acquisitions, net of cash acquired	(19,793,000)	0	0
Collection of deferred purchase price receivables	1,213,497,000	833,958,000	540,944,000
Sale of investments	75,942,000	396,000	0
Other investing activities	7,690,000	2,097,000	0
Net cash provided by investing activities	1,239,028,000	810,663,000	499,135,000
Financing activities:
Dividends paid	(101,111,000)	(75,183,000)	(100,442,000)
Repurchases of common stock	(35,000,000)	0	0
Proceeds from issuance of long-term debt	0	0	300,000,000
Debt issuance costs	0	0	(3,300,000)
Payments on long-term debt	(100,750,000)	0	(460,840,000)
(Payment) draw on revolving credit	(24,000,000)	53,000,000	0
Other financing activities	7,627,000	(462,000)	(6,647,000)
Net cash used in financing activities	(253,234,000)	(22,645,000)	(271,229,000)
Effect of exchange rate changes on cash	(6,030,000)	7,801,000	(2,064,000)
Net change in cash and cash equivalents	(1,230,000)	65,300,000	(17,702,000)
Cash and cash equivalents at beginning of period	143,244,000	77,944,000	95,646,000
Cash and cash equivalents at end of period	142,014,000	143,244,000	77,944,000
Supplemental disclosures:
Income taxes paid	83,549,000	48,924,000	12,021,000
Interest paid	14,633,000	15,234,000	25,742,000
Supplemental disclosure of non-cash investing activity:
Retained interest in securitization transactions	$ 1,122,627,000	$ 900,578,000	$ 707,395,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Apr. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Description of Business Patterson Companies, Inc. (referred to herein as “Patterson” or in the first person notations “we,” “our,” and “us”) is a value-added specialty distributor serving the U.S. and Canadian dental supply and the U.S., Canadian and U.K. animal health supply markets. Patterson has three reportable segments: Dental, Animal Health and Corporate. Basis of Presentation The consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding"), PDC Funding Company II, LLC ("PDC Funding II"), PDC Funding Company III, LLC ("PDC Funding III") and PDC Funding Company IV, LLC ("PDC Funding IV") , which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. PDC Funding III and PDC Funding IV are fully consolidated special purpose entity established to sell certain receivables to unaffiliated financial institutions. The assets of PDC Funding, PDC Funding II, PDC Funding III and PDC Funding IV would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding, PDC Funding II, PDC Funding III or PDC Funding IV. The consolidated financial statements also include the assets and liabilities of Technology Partner Innovations, LLC, which is further described in Note 13. Fiscal Year End We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. Fiscal 2022 ended on April 30, 2022 and consisted of 53 weeks. Fiscal 2021 and 2020 ended on April 24, 2021 and April 25, 2020, respectively, and both consisted of 52 weeks. Fiscal 2023 will end on April 29, 2023 and will consist of 52 weeks. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash equivalents consist primarily of investments in money market funds and government securities. The maturity of these securities at the time of purchase is 90 days or less. All cash and cash equivalents are classified as available-for-sale and carried at fair value, which approximates cost. Inventory Inventory consists of merchandise held for sale and is stated at the lower of cost or market. The cost of our inventory includes the amount we pay to our suppliers to acquire inventory and freight costs incurred in connection with the delivery of product to our distribution centers and our other locations. Cost is determined using the last-in, first-out ("LIFO") method for all inventories, except for foreign inventories, which are valued using the first-in, first-out ("FIFO") method. Inventories valued at LIFO represented 85% and 83% of total inventories at April 30, 2022 and April 24, 2021, respectively. The accumulated LIFO reserve was $130,959 at April 30, 2022 and $120,775 at April 24, 2021. We believe that inventory replacement cost exceeds the inventory balance by an amount approximating the LIFO reserve. Property and Equipment Property and equipment are stated at cost. Depreciation is calculated on the straight-line method over estimated useful lives of up to 39 years for buildings or the expected remaining life of purchased buildings, the term of the lease for leasehold improvements, 3 to 10 years for computer hardware and software, and 5 to 10 years for furniture and equipment. Goodwill and Other Indefinite-Lived Intangible Assets Goodwill represents the excess of cost over the fair value of identifiable net assets of businesses acquired. Impairment testing for goodwill is done at the reporting unit level, with all goodwill assigned to a reporting unit. We have two reporting units as of April 30, 2022; Dental and Animal Health. Our Corporate reportable segment's assets and liabilities, and net sales and expenses, are allocated to the two reporting units. We assess goodwill for impairment annually and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Any goodwill impairment is measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. The determination of fair value involves uncertainties because it requires management to make assumptions and to apply judgment to estimate industry and economic factors and the profitability of future business strategies. Patterson conducts impairment testing based on current business strategy in light of present industry and economic conditions, as well as future expectations. Additionally, in assessing goodwill for impairment, the reasonableness of the implied control premium is considered based on market capitalizations and recent market transactions. Our indefinite-lived intangible asset is a trade name, which is assessed for impairment by comparing the carrying value of the asset with its fair value. If the carrying value exceeds fair value, an impairment loss is recognized in an amount equal to the excess. The determination of fair value involves assumptions, including projected revenues and gross profit levels, as well as consideration of any factors that may indicate potential impairment. In connection with the preparation of these financial statements in the fourth quarter of fiscal 2022, management completed its annual goodwill and other indefinite-lived intangible asset impairment tests using the beginning of our fiscal 2022 fourth quarter as the valuation date. We determined that there was no impairment of either goodwill or our indefinite-lived intangible asset. In connection with the preparation of our fiscal 2021 Form 10-K in the fourth quarter of fiscal 2021, management completed its annual goodwill and other indefinite-lived intangible asset impairment tests using the beginning of our fiscal 2021 fourth quarter as the valuation date. We determined that there was no impairment of either goodwill or our indefinite-lived intangible asset. In connection with the preparation of our fiscal 2020 Form 10-K in the fourth quarter of fiscal 2020, management completed its annual goodwill and other indefinite-lived intangible asset impairment tests using the beginning of our fiscal 2020 fourth quarter as the valuation date. We determined that there was no impairment of our indefinite-lived intangible asset. Our annual goodwill impairment test resulted in no impairment to the Dental reporting unit’s goodwill, and a $269,000 non-cash pre-tax impairment charge of our Animal Health reporting unit’s goodwill. The decrease in the fair value of the Animal Health reporting unit below its carrying value was mainly the result of a reduction in management’s estimates of future cash flows. Future cash flows were affected by a reduction in future sales volume and operating margins. The sales volume estimate reflected recent sales trends we had experienced. Future operating margins are expected to be lower based on then-current trends in our markets. These trends were driven by customer and vendor consolidation. Subsequent to the annual test being completed and in connection with the preparation of our fiscal 2020 Form 10-K in the fourth quarter of fiscal 2020, we experienced events and circumstances that indicated that the carrying amount of goodwill may have been further impaired. These events and circumstances included a decline in our projected future earnings and a sustained decrease in our share price. As such, we tested our goodwill for impairment as of the beginning of our fiscal April 2020. This test resulted in no impairment to the Dental reporting unit’s goodwill, and a $406,055 non-cash pre-tax impairment charge of our Animal Health reporting unit’s goodwill. The decrease in the fair value of the Animal Health reporting unit subsequent to the annual goodwill impairment test was caused by additional reductions in management’s estimates of future cash flows, driven by reduced sales volumes, as well as reduced EBITDA multiples of comparable companies. These estimates and market multiples were negatively affected by COVID-19. In fiscal 2020, the animal health industry experienced a reduction in sales volume as a result of stay at home and shelter in place orders, as well as a result of meat packing plant closures. Our future cash flow estimates for this business unit in fiscal 2020 reflected the long-term impact of COVID-19. As of April 25, 2020, our Animal Health reporting unit had no remaining goodwill as a result of the total goodwill impairment charges recorded in fiscal 2020 of $675,055. Long-Lived Assets Long-lived assets, including definite-lived intangible assets, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. Our definite-lived intangible assets primarily consist of customer relationships, trade names and trademarks. When impairment exists, the related assets are written down to fair value using level 3 inputs, as discussed further in Note 7. Other Non-current Assets, Net April 30, 2022 April 24, 2021 Development costs of software to be sold, net $ 64,513 $ 68,156 Other 42,995 21,703 Other non-current assets, net $ 107,508 $ 89,859 During fiscal 2022, 2021 and 2020, we recorded $7,267, $2,346 and $0, respectively, of amortization expense related to the development costs of software to be sold in cost of sales within the consolidated statements of operations and other comprehensive income (loss). Development Costs of Software to be Sold At the end of each fiscal quarter, we compare the unamortized capitalized costs of software to be sold to its net realizable value. If the unamortized amount exceeds the net realizable value, an impairment is recorded for this amount of that asset shall be written off. If the unamortized capitalized costs are less than the net realizable value of that asset, then there is no impairment. Financial Instruments We account for derivative financial instruments under the provisions of Accounting Standards Codification ("ASC") Topic 815, “Derivatives and Hedging.” Our use of derivative financial instruments is generally limited to managing well-defined interest rate risks. We do not use financial instruments or derivatives for any trading purposes. Revenue Recognition Revenues are generated from the sale of consumable products, equipment and support, software and support, technical service parts and labor, and other sources. Revenues are recognized when or as performance obligations are satisfied. Performance obligations are satisfied when the customer obtains control of the goods or services. Consumable, equipment, software and parts sales are recorded upon delivery, except in those circumstances where terms of the sale are FOB shipping point, in which case sales are recorded upon shipment. Technical service labor is recognized as it is provided. Revenue derived from equipment and software support is recognized ratably over the period in which the support is provided. In addition to revenues generated from the distribution of consumable products under arrangements (buy/sell agreements) where the full market value of the product is recorded as revenue, we earn commissions for services provided under agency agreements. The agency agreement contrasts to a buy/sell agreement in that we do not have control over the transaction, as we do not have the primary responsibility of fulfilling the promise of the good or service and we do not bill or collect from the customer in an agency relationship. Commissions under agency agreements are recorded when the services are provided. Estimates for returns, damaged goods, rebates, loyalty programs and other revenue allowances are made at the time the revenue is recognized based on the historical experience for such items. The receivables that result from the recognition of revenue are reported net of related allowances. We maintain a valuation allowance based upon the expected collectability of receivables held. Estimates are used to determine the valuation allowance and are based on several factors, including historical collection data, economic trends and credit worthiness of customers. Receivables are written off when we determine the amounts to be uncollectible, typically upon customer bankruptcy or non-response to continuous collection efforts. The portions of receivable amounts that are not expected to be collected during the next twelve months are classified as long-term. Patterson has a relatively large, dispersed customer base and no single customer accounts for more than 10% of consolidated net sales. In addition, the equipment sold to customers under finance contracts generally serves as collateral for the contract and the customer provides a personal guarantee as well. Net sales do not include sales tax as we are considered a pass-through conduit for collecting and remitting sales tax. Contract Balances Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities. Contract asset balances as of April 30, 2022 and April 24, 2021 were $134 and $2,491, respectively. Our contract liabilities primarily relate to advance payments from customers, upfront payments for software and support provided over time, and options that provide a material right to customers, such as our customer loyalty programs. At April 30, 2022 and April 24, 2021, contract liabilities of $38,581 and $23,526 were reported in other accrued liabilities, respectively. During the fiscal year ended April 30, 2022, we recognized $20,658 of the amount previously deferred at April 24, 2021. Patterson Advantage Loyalty Program The Dental segment provides a point-based awards program to qualifying customers involving the issuance of “Patterson Advantage dollars” which can be used toward equipment and technology purchases. Patterson Advantage dollars earned during a program year expire one year after the end of the program year. The cost and corresponding liability associated with the program are recognized as contra-revenue. As of April 30, 2022, we believe we have sufficient experience with the program to reasonably estimate the amount of Patterson Advantage dollars that will not be redeemed and thus have recorded a liability for 88.0% of the maximum potential amount that could be redeemed. We recognize the expected breakage amount as revenue in proportion to the pattern of rights exercised by the customer, and we recognize the estimated value of unused Patterson Advantage dollars as redemptions occur. Breakage recognized was immaterial to all periods presented. Freight and Delivery Charges Freight and delivery charges are included in cost of sales in the consolidated statements of operations and other comprehensive income (loss). Advertising We expense all advertising and promotional costs as incurred, except for direct marketing expenses, which are expensed over the shorter of the life of the asset or one year. Total net advertising and promotional expenses were $1,532, $134 and $5,793 for fiscal 2022, 2021 and 2020, respectively. There were no deferred direct-marketing expenses included in the consolidated balance sheets as of April 30, 2022 and April 24, 2021. Related Party Transactions We have interests in a number of entities that are accounted for using the equity method. During fiscal 2022, 2021 and 2020, we made purchases of $128,452, $110,210 and $94,238 from these entities, respectively. During fiscal 2022, 2021 and 2020, we recorded net sales of $117,347, $93,577 and $110,262 to these entities, respectively. Income Taxes The liability method is used to account for income tax expense. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established for deferred tax assets if, after assessment of available positive and negative evidence, it is more likely than not that the deferred tax asset will not be fully realized. Self-insurance Patterson is self-insured for certain losses related to general liability, product liability, automobile, workers’ compensation and medical claims. We estimate our liabilities based upon an analysis of historical data and actuarial estimates. While current estimates are believed reasonable based on information currently available, actual results could differ and affect financial results due to changes in the amount or frequency of claims, medical cost inflation or other factors. Historically, actual results related to these types of claims have not varied significantly from estimated amounts. Stock-based Compensation We recognize stock-based compensation expense based on estimated grant date fair values. The grant date fair value of stock options and stock purchases made through our Employee Stock Purchase Plan are estimated using the Black-Scholes option pricing valuation model. The grant date fair value of performance stock units that vest upon meeting certain market conditions is estimated using the Monte Carlo valuation model. These valuations require estimates to be made including expected stock price volatility which considers historical volatility trends, implied future volatility based on certain traded options and other factors. We estimate the expected life of awards based on several factors, including types of participants, vesting schedules, contractual terms and various factors surrounding exercise behavior of different groups. The grant date fair value of time-based restricted stock awards and restricted stock units is calculated based on the closing price of our common stock on the date of grant. Compensation expense for all share-based payment awards is recognized over the requisite service period (or to the date a participant becomes eligible for retirement, if earlier) for awards that are expected to vest. Other Income (Expense), Net Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Gain (loss) on interest rate swap agreements $ 15,835 $ 1,151 $ (18,712) Investment income and other 11,896 12,457 7,877 Other income (expense), net $ 27,731 $ 13,608 $ (10,835) Comprehensive Income (Loss) Comprehensive income (loss) is computed as net income (loss) plus certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income (loss) are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. The income tax expense related to cash flow hedge losses was $321, $321 and $2,460 for fiscal 2022, 2021 and 2020, respectively. Earnings (Loss) Per Share ("EPS") The amount of basic EPS is computed by dividing net income (loss) attributable to Patterson Companies, Inc. by the weighted average number of outstanding common shares during the period. The amount of diluted EPS is computed by dividing net income (loss) by the weighted average number of outstanding common shares and common share equivalents, when dilutive, during the period. The following table sets forth the denominator for the computation of basic and diluted EPS. There were no material adjustments to the numerator. Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Denominator for basic EPS – weighted average shares 97,277 95,599 94,154 Effect of dilutive securities – stock options, restricted stock and stock purchase plans 1,237 1,065 — Denominator for diluted EPS – weighted average shares 98,514 96,664 94,154 Potentially dilutive securities representing 772, 1,014 and 2,517 shares for fiscal 2022, 2021 and 2020, respectively, were excluded from the calculation of diluted EPS because their effects were anti-dilutive using the treasury stock method. For the fiscal year ended April 25, 2020, 905 incremental shares related to dilutive securities were not included in the diluted EPS calculation because we reported a loss for this period. Shares related to dilutive securities have an anti-dilutive impact on EPS when a net loss is reported and therefore are not included in the calculation. Recent Accounting Pronouncements The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” in March 2020 and ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope” in January 2021. These ASUs provide temporary optional expedients and exceptions to existing guidance on contract modifications and hedge accounting to facilitate the market transition from existing reference rates, such as LIBOR which began to be phased out at the end of 2021, to alternate reference rates. These standards were effective upon issuance. We are evaluating the optional relief guidance provided within these ASUs, and are reviewing our debt securities, derivative instruments and customer financing contracts that currently utilize LIBOR as the reference rate.

Acquisitions

Acquisitions	12 Months Ended
	Apr. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	AcquisitionsDuring the first quarter of fiscal 2022, we acquired substantially all of the assets of Miller Vet Holdings, LLC, a multiregional veterinary distributor, for total cash consideration of $19,793 and liabilities assumed of $6,799. We have included its results of operations in our financial statements since the date of acquisition within our Animal Health segment. This acquisition is expected to grow our presence in the companion animal market and drive increased operating leverage and synergies. As of the acquisition date, we recorded $14,000 of identifiable intangibles, $1,063 of goodwill and net tangible assets of $4,796 in our consolidated balance sheets related to this acquisition. Goodwill, which is deductible for income tax purposes, was reduced by $66 subsequent to the acquisition date as a result of working capital adjustments. The accounting for the acquisition was complete as of April 30, 2022. The acquisition did not materially impact our financial statements, and therefore pro forma results are not provided.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Apr. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consisted of the following: April 30, 2022 April 24, 2021 Cash on hand $ 138,828 $ 141,546 Money market funds 3,186 1,698 Total $ 142,014 $ 143,244 Cash on hand is generally in interest earning accounts. Included in cash and cash equivalents in the consolidated balance sheets are $39,106 and $36,771 as of April 30, 2022 and April 24, 2021, respectively, which represent cash collected from previously sold customer financing contracts that have not yet been settled. See Note 5 for additional information.

Receivables Securitization Prog

Receivables Securitization Program	12 Months Ended
	Apr. 30, 2022
Transfers and Servicing [Abstract]
Receivables Securitization Program	Receivables Securitization Program We are party to certain receivables purchase agreements (the “Receivables Purchase Agreements”) with MUFG Bank, Ltd. ("MUFG") (f.k.a. The Bank of Tokyo-Mitsubishi UFJ, Ltd.), under which MUFG acts as an agent to facilitate the sale of certain Patterson receivables (the “Receivables”) to certain unaffiliated financial institutions (the “Purchasers”). The sale of these receivables is accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing. We utilize PDC Funding III and PDC Funding IV to facilitate the sale to fulfill requirements within the agreement. We use a daily unit of account for these Receivables. The proceeds from the sale of these Receivables comprise a combination of cash and a deferred purchase price (“DPP”) receivable. The DPP receivable is ultimately realized by Patterson following the collection of the underlying Receivables sold to the Purchasers. The amount available under the Receivables Purchase Agreements fluctuates over time based on the total amount of eligible Receivables generated during the normal course of business, with maximum availability of $200,000 as of April 30, 2022, of which $200,000 was utilized. We have no retained interests in the transferred Receivables, other than our right to the DPP receivable and collection and administrative service fees. We consider the fees received adequate compensation for services rendered, and accordingly have recorded no servicing asset or liability. As of April 30, 2022 and April 24, 2021, the fair value of outstanding trade receivables transferred to the Purchasers under the facility and derecognized from the consolidated balance sheets were $396,443 and $384,950, respectively. Sales of trade receivables under this facility were $3,643,700, $3,171,456, and $2,068,409, and cash collections from customers on receivables sold were $3,632,145, $3,094,060 and $2,128,394 during the fiscal years ended 2022, 2021 and 2020, respectively. The DPP receivable is recorded at fair value within the consolidated balance sheets within prepaid expenses and other current assets. The difference between the carrying amount of the Receivables and the sum of the cash and fair value of the DPP receivable received at time of transfer is recognized as a gain or loss on sale of the related Receivables inclusive of bank fees and allowance for credit losses. In operating expenses in the consolidated statements of operations and other comprehensive income (loss), we recorded a loss of $3,247, $3,338 and $7,242 during fiscal 2022, 2021 and 2020, respectively, related to the Receivables. The following summarizes the activity related to the DPP receivable: Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Beginning DPP receivable balance $ 183,999 $ 117,327 $ 57,238 Non-cash additions to DPP receivable 1,052,938 768,619 552,751 Cash collections on DPP receivable (1,041,173) (701,947) (492,662) Ending DPP receivable balance $ 195,764 $ 183,999 $ 117,327

Customer Financing

Customer Financing	12 Months Ended
	Apr. 30, 2022
Receivables [Abstract]
Customer Financing	Customer Financing As a convenience to our customers, we offer several different financing alternatives, including a third party program and a Patterson-sponsored program. For the third party program, we act as a facilitator between the customer and the third party financing entity with no on-going involvement in the financing transaction. Under the Patterson-sponsored program, equipment purchased by creditworthy customers may be financed up to a maximum of $1,000. We generally sell our customers’ financing contracts to outside financial institutions in the normal course of our business. These financing arrangements are accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing . We currently have two arrangements under which we sell these contracts. We use a monthly unit of account for these financing contracts. First, we operate under an agreement to sell a portion of our equipment finance contracts to commercial paper conduits with MUFG serving as the agent. We utilize PDC Funding to fulfill a requirement of participating in the commercial paper conduit. We receive the proceeds of the contracts upon sale to MUFG. At least 15.0% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with MUFG. The capacity under the agreement with MUFG at April 30, 2022 was $525,000. Second, we maintain an agreement with Fifth Third Bank ("Fifth Third") whereby Fifth Third purchases customers’ financing contracts. PDC Funding II sells its financing contracts to Fifth Third. We receive the proceeds of the contracts upon sale to Fifth Third. At least 15.0% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with Fifth Third. The capacity under the agreement with Fifth Third at April 30, 2022 was $100,000. We service the financing contracts under both arrangements, for which we are paid a servicing fee. The servicing fees we receive are considered adequate compensation for services rendered. Accordingly, no servicing asset or liability has been recorded. The portion of the purchase price for the receivables held by the conduits is deemed a DPP receivable, which is paid to the applicable special purpose entity as payments on the customers’ financing contracts are collected by Patterson from customers. The difference between the carrying amount of the receivables sold under these programs and the sum of the cash and fair value of the DPP receivable received at time of transfer is recognized as a gain on sale of the related receivables and recorded in net sales in the consolidated statements of operations and other comprehensive income (loss). Expenses incurred related to customer financing activities are recorded in operating expenses in our consolidated statements of operations and other comprehensive income (loss). During fiscal 2022, 2021 and 2020, we sold $314,732, $369,497 and $357,616 of contracts under these arrangements, respectively. In net sales in the consolidated statements of operations and other comprehensive income (loss), we recorded a loss of $18,379 and $2,048 during fiscal 2022 and 2021, respectively, and a gain of $43,919 during fiscal 2020, related to these contracts sold. Cash collections on financed receivables sold were $426,188, $401,535 and $346,077 during the fiscal years ended 2022, 2021 and 2020, respectively. Included in cash and cash equivalents in the consolidated balance sheets are $39,106 and $36,771 as of April 30, 2022 and April 24, 2021, respectively, which represent cash collected from previously sold customer financing contracts that have not yet been settled. Included in current receivables in the consolidated balance sheets are $58,190 and $50,638 as of April 30, 2022 and April 24, 2021, respectively, of finance contracts we have not yet sold. A total of $575,231 of finance contracts receivable sold under the arrangements was outstanding at April 30, 2022. Since the internal financing program began in 1994, bad debt write-offs have amounted to less than 1% of the loans originated. The following summarizes the activity related to the DPP receivable: Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Beginning DPP receivable balance $ 227,967 $ 228,019 $ 121,657 Non-cash additions to DPP receivable 69,689 131,959 154,644 Cash collections on DPP receivable (172,324) (132,011) (48,282) Ending DPP receivable balance $ 125,332 $ 227,967 $ 228,019 The arrangements require us to maintain a minimum current ratio and maximum leverage ratio. We were in compliance with those covenants at April 30, 2022.

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Apr. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments We are a party to certain offsetting and identical interest rate cap agreements entered into to fulfill certain covenants of the equipment finance contract sale agreements. The interest rate cap agreements also provide a credit enhancement feature for the financing contracts sold by PDC Funding and PDC Funding II to the commercial paper conduit. The interest rate cap agreements are canceled and new agreements are entered into periodically to maintain consistency with the dollar maximum of the sale agreements and the maturity of the underlying financing contracts. As of April 30, 2022, PDC Funding had purchased an interest rate cap from a bank with a notional amount of $525,000 and a maturity date of August 2029. We sold an identical interest rate cap to the same bank. As of April 30, 2022, PDC Funding II had purchased an interest rate cap from a bank with a notional amount of $100,000 and a maturity date of September 2028. We sold an identical interest rate cap to the same bank. These interest rate cap agreements do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change in fair value as income or expense during the period in which the change occurs. In January 2014, we entered into a forward interest rate swap agreement with a notional amount of $250,000 and accounted for it as a cash flow hedge, in order to hedge interest rate fluctuations in anticipation of refinancing the 5.17% senior notes due March 25, 2015. These notes were repaid on March 25, 2015 and replaced with new $250,000 3.48% senior notes due March 24, 2025. A cash payment of $29,003 was made in March 2015 to settle the interest rate swap. This amount is recorded in other comprehensive income (loss), net of tax, and is recognized as interest expense over the life of the related debt. In fiscal 2020, we repaid certain indebtedness, resulting in accelerating a portion of this interest expense and recording a pre-tax non-cash charge of $8,134. See Note 11 for additional information. We utilize forward interest rate swap agreements to hedge against interest rate fluctuations that impact the amount of net sales we record related to our customer financing contracts. These interest rate swap agreements do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change in fair value as income or expense during the period in which the change occurs. As of April 24, 2021, the remaining notional amount for interest rate swap agreements was $653,122, with the latest maturity date in fiscal 2028. During fiscal 2022, we entered into forward interest rate swap agreements with a notional amount of $179,818. As of April 30, 2022, the remaining notional amount for interest rate swap agreements was $574,144, with the latest maturity date in fiscal 2029. Net cash payments of $6,770 and $9,373 were made in fiscal 2022 and 2021, respectively, to settle a portion of our liabilities related to these interest rate swap agreements. These payments are reflected as cash outflows in the consolidated statements of cash flows within net cash used in operating activities. The following presents the fair value of derivative instruments included in the consolidated balance sheets: Derivative type Classification April 30, 2022 April 24, 2021 Assets: Interest rate contracts Prepaid expenses and other current assets $ 3,875 $ — Interest rate contracts Other non-current assets 19,871 2,120 Total asset derivatives $ 23,746 $ 2,120 Liabilities: Interest rate contracts Other accrued liabilities $ 250 $ 3,776 Interest rate contracts Other non-current liabilities 10,013 7,795 Total liability derivatives $ 10,263 $ 11,571 The following tables present the pre-tax effect of derivative instruments on the consolidated statements of operations and other comprehensive income (loss): Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion) Fiscal Year Ended Derivatives in cash flow hedging relationships Statements of operations April 30, 2022 April 24, 2021 April 25, 2020 Interest rate contracts Interest expense $ (1,363) $ (1,363) $ (10,458) Amount of Gain (Loss) Recognized in Income on Derivatives Fiscal Year Ended Derivatives not designated as hedging instruments Statements of operations April 30, 2022 April 24, 2021 April 25, 2020 Interest rate contracts Other income, net $ 15,835 $ 1,151 $ (18,712) There were no gains or losses recognized in other comprehensive income (loss) on cash flow hedging derivatives in fiscal 2022, 2021 or 2020. We recorded no ineffectiveness during fiscal 2022, 2021 or 2020. As of April 30, 2022, the estimated pre-tax portion of accumulated other comprehensive loss that is expected to be reclassified into earnings over the next twelve months is $1,363, which will be recorded as an increase to interest expense.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Apr. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value MeasurementsFair value is the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. The fair value hierarchy of measurements is categorized into one of three levels based on the lowest level of significant input used: Level 1 – Quoted prices in active markets for identical assets and liabilities at the measurement date. Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 – Unobservable inputs for which there is little or no market data available. These inputs reflect Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows: April 30, 2022 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 3,186 $ 3,186 $ — $ — DPP receivable - receivables securitization program 195,764 — — 195,764 DPP receivable - customer financing 125,332 — — 125,332 Derivative instruments 23,746 — 23,746 — Total assets $ 348,028 $ 3,186 $ 23,746 $ 321,096 Liabilities: Derivative instruments $ 10,263 $ — $ 10,263 $ — April 24, 2021 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 1,698 $ 1,698 $ — $ — DPP receivable - receivables securitization program 183,999 — — 183,999 DPP receivable - customer financing 227,967 — — 227,967 Derivative instruments 2,120 — 2,120 — Total assets $ 415,784 $ 1,698 $ 2,120 $ 411,966 Liabilities: Derivative instruments $ 11,571 $ — $ 11,571 $ — Cash equivalents – We value cash equivalents at their current market rates. The carrying value of cash equivalents approximates fair value and maturities are less than three months. DPP receivable - receivables securitization program – We value this DPP receivable based on a discounted cash flow analysis using unobservable inputs, which include the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant. DPP receivable - customer financing – We value this DPP receivable based on a discounted cash flow analysis using unobservable inputs, which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant. Derivative instruments –Our derivative instruments consist of interest rate cap agreements and interest rate swaps. These instruments are valued using inputs such as interest rates and credit spreads. Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments under certain circumstances. We adjust the carrying value of our non-marketable equity securities to fair value when observable transactions of identical or similar securities occur, or due to an impairment. In fiscal 2022, we sold a portion of our investment in Vetsource, with a carrying value of $25,814, for $56,849. We recorded a pre-tax gain of $31,035 in gains on investments in our consolidated statements of operations and other comprehensive income (loss) as a result of this sale. The cash received of $56,849 is reported within investing activities in our consolidated statements of cash flows. In fiscal 2022, we also recorded a pre-tax non-cash gain of $31,035 to reflect the increase in the carrying value of the remaining portion of our investment in Vetsource, which was based on the selling price of the portion of the investment we sold for $56,849. This gain was recorded in gains on investments in our consolidated statements of operations and other comprehensive income (loss). The carrying value of the investment we owned following this sale was $56,849 and $25,814 as of April 30, 2022 and April 24, 2021, respectively. Concurrent with the sale completed in fiscal 2022, we obtained rights that will allow us, under certain circumstances, to require another shareholder of Vetsource to purchase our remaining shares. We recorded a pre-tax non-cash gain of $25,757 in gains on investments in our consolidated statements of operations and other comprehensive income (loss) as a result of this transaction. The carrying value of this put option as of April 30, 2022 is $25,757, and is reported within investments in our consolidated balance sheets. The aggregate gains on investments of $87,827 are reported within operating activities in our consolidated statements of cash flows. Concurrent with obtaining this put option, we also granted rights to the same Vetsource shareholder that would allow such shareholder, under certain circumstances, to require us to sell our remaining shares at fair value. In fiscal 2022, we sold a portion of our investment in Vets Plus with a carrying value of $4,009 for $17,101. We recorded a pre-tax gain of $13,092 in gains on investments in our consolidated statements of operations and other comprehensive income (loss) as a result of this sale. This $13,092 pre-tax gain is reported within operating activities in our consolidated statements of cash flows. The cash received of $17,101 is reported within investing activities in our consolidated statements of cash flows. The carrying value of the investment we owned following this sale was $2,355 and $2,355 as of April 30, 2022 and April 24, 2021, respectively. In fiscal 2020, we recorded a pre-tax gain of $34,334 related to one of our investments in other income, net in our consolidated statements of operations and other comprehensive income (loss). This gain was based on the selling price of preferred stock in this investment that is similar to the preferred stock we own, and was adjusted for differences in liquidation preferences. As of April 25, 2020, this investment had a carrying value of $51,628. There were no fair value adjustments to such assets in fiscal 2021. Our debt is not measured at fair value in the consolidated balance sheets. The estimated fair value of our debt as of April 30, 2022 and April 24, 2021 was $489,777 and $610,811, respectively, as compared to a carrying value of $488,554 and $588,295 at April 30, 2022 and April 24, 2021, respectively. The fair value of debt was measured using a discounted cash flow analysis based on expected market based yields (i.e., level 2 inputs). The carrying amounts of receivables, net of allowances, accounts payable, and certain accrued and other current liabilities approximated fair value at April 30, 2022 and April 24, 2021.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Apr. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in the carrying value of goodwill for each of our reportable segments for the fiscal year ended April 30, 2022 were as follows: Balance at April 24, 2021 Acquisition Foreign Currency Translation Balance at April 30, 2022 Dental $ 139,932 $ — $ (299) $ 139,633 Animal Health — 997 — 997 Corporate — — — — Total $ 139,932 $ 997 $ (299) $ 140,630 Balances of other intangible assets, excluding goodwill, were as follows: April 30, 2022 April 24, 2021 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Unamortized - indefinite lived: Trade name $ 12,300 $ — $ 12,300 $ 12,300 $ — $ 12,300 Amortized - definite lived: Customer relationships 366,969 181,280 185,689 355,685 159,376 196,309 Trade names and trademarks 132,996 95,903 37,093 133,834 85,221 48,613 Developed technology and other 65,757 48,225 17,532 72,398 49,976 22,422 Total amortized intangible assets 565,722 325,408 240,314 561,917 294,573 267,344 Total identifiable intangible assets $ 578,022 $ 325,408 $ 252,614 $ 574,217 $ 294,573 $ 279,644 With respect to the amortized intangible assets, future amortization expense is expected to approximate $37,357, $36,699, $36,694, $26,884 and $25,491 for fiscal 2023, 2024, 2025, 2026 and 2027, respectively. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, changes in foreign currency exchange rates, impairment of intangible assets, accelerated amortization of intangible assets and other events.

Property and Equipment

Property and Equipment	12 Months Ended
	Apr. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consisted of the following: April 30, 2022 April 24, 2021 Land $ 11,341 $ 12,014 Buildings 106,957 118,582 Leasehold improvements 31,395 31,125 Furniture and equipment 187,093 188,594 Computer hardware and software 254,205 244,537 Construction-in-progress (1) 30,502 17,665 Property and equipment, gross 621,493 612,517 Accumulated depreciation (408,353) (393,079) Property and equipment, net $ 213,140 $ 219,438 (1) Includes $8,585 and $6,326 of unamortized development costs of software to be sold as of April 30, 2022 and April 24, 2021, respectively.

Lease Commitments

Lease Commitments	12 Months Ended
	Apr. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Leases	Leases We lease certain warehouses, office space, vehicles and equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. We recognize lease expense for these leases on a straight-line basis over the lease term. We do not separate lease and non-lease components, and instead account for each lease and non-lease component associated with that lease as a single lease component. Some leases include one or more options to renew. The exercise of renewal options is at our sole discretion. Our lease agreements do not contain significant residual value guarantees, restrictions or covenants. Total lease costs for the fiscal year ended April 30, 2022 and April 24, 2021 were $35,646 and $34,712, respectively, which include variable lease costs and short-term lease costs, which were immaterial. The following table presents future maturities of lease liabilities: 2023 $ 31,165 2024 21,793 2025 12,650 2026 6,168 2027 2,941 After 2027 1,222 Total lease payments 75,939 Less: imputed interest (3,259) Present value of lease liabilities $ 72,680 The following tables present other supplemental information related to leases: Fiscal Year Ended April 30, 2022 April 24, 2021 Cash paid for amounts included in the measurement of operating lease liabilities $ 38,192 $ 37,054 Lease assets obtained in exchange for new operating lease liabilities $ 31,132 $ 50,114 April 30, 2022 April 24, 2021 Weighted-average remaining lease term - operating leases 2.98 years 3.06 years Weighted-average discount rate - operating leases 3.10 % 3.31 %

Debt

Debt	12 Months Ended
	Apr. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt Our long-term debt consisted of the following: Carrying Value Interest Rate April 30, 2022 April 24, 2021 Senior notes due fiscal 2022 (1) 3.59 % $ — $ 100,750 Senior notes due fiscal 2024 (1) 3.74 % 33,000 33,000 Senior notes due fiscal 2025 (2) 3.48 % 117,500 117,500 Senior notes due fiscal 2028 (3) 3.79 % 40,000 40,000 Term loan due fiscal 2024 (4) 1.89 % 300,000 300,000 Less: Deferred debt issuance costs (1,946) (2,955) Total debt 488,554 588,295 Less: Current maturities of long-term debt — (100,750) Long-term debt $ 488,554 $ 487,545 (1) Issued in December 2011. (2) Issued in March 2015. (3) Issued in March 2018. (4) Issued in December 2019, amended in February 2021. Interest rate is 1-month LIBOR plus 1.13% as of April 30, 2022. Future principal payments due, based on stated contractual maturities for our long-term debt, were as follows as of April 30, 2022: Fiscal Year 2023 $ — 2024 333,000 2025 117,500 2026 — 2027 — Thereafter 40,000 Total $ 490,500 In fiscal 2021, we entered into an amendment, restatement and consolidation of certain credit agreements with various lenders, including MUFG Bank, Ltd, as administrative agent. This amended and restated credit agreement (the “Credit Agreement”), dated February 16, 2021, consists of a $700,000 revolving credit facility and a $300,000 term loan facility, and will mature no later than February 2024. We used the facilities to refinance and consolidate certain credit agreements in existence prior to the Credit Agreement being executed, pay the fees and expenses incurred therewith, and finance our ongoing working capital and other general corporate purposes. As of April 30, 2022, $300,000 was outstanding under the Credit Agreement term loan at an interest rate of 1.89% and $29,000 was outstanding under the Credit Agreement revolving credit facility at an interest rate of 1.54%. In fiscal 2020, we repaid certain indebtedness totaling $373,750, and as a result, we recorded a pre-tax non-cash charge of $8,984 in fiscal 2020. This charge relates to the January 2014 forward interest rate swap agreement and accelerated amortization of debt issuance costs. We are subject to various financial covenants under our debt agreements including the maintenance of leverage and interest coverage ratios. In the event of our default, any outstanding obligations may become due and payable immediately. We were in compliance with the covenants under our debt agreements as of April 30, 2022.

Income Taxes

Income Taxes	12 Months Ended
	Apr. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of income (loss) before taxes were as follows: Fiscal Year Ended April 30, April 24, April 25, Income (loss) before taxes United States $ 225,195 $ 166,251 $ (594,431) International 41,059 33,680 4,024 Total $ 266,254 $ 199,931 $ (590,407) Significant components of income tax expense (benefit) were as follows: Fiscal Year Ended April 30, April 24, April 25, Current: Federal $ 46,964 $ 36,836 $ 18,300 Foreign 11,968 9,975 7,501 State 10,326 8,771 4,959 Total current expense 69,258 55,582 30,760 Deferred: Federal (3,918) (7,529) (25,918) Foreign (217) (362) 164 State (583) (2,869) (6,046) Total deferred benefit (4,718) (10,760) (31,800) Income tax expense (benefit) $ 64,540 $ 44,822 $ (1,040) On March 27, 2020, the “Coronavirus Aid, Relief and Economic Security (CARES) Act” was signed into law. The CARES Act, among other things, includes provisions relating to refundable employment tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. These benefits did not materially impact the Company’s effective tax rate for the fiscal years ended April 30, 2022, April 24, 2021 or April 25, 2020. Deferred tax assets and liabilities are included in other non-current assets and deferred income taxes on the consolidated balance sheets. Significant components of our deferred tax assets (liabilities) were as follows: April 30, April 24, 2021 1 Deferred tax assets: Employee compensation and benefits $ 9,352 $ 12,223 Inventory related items 9,985 12,250 Foreign deferred assets, net 11,812 9,510 Foreign tax credit 7,037 7,112 Lease liability 14,416 16,153 Accrued charitable contributions 6,559 — Other accrued liabilities 6,642 7,331 Other 5,190 5,372 Gross deferred tax assets 70,993 69,951 Less: Valuation allowance (18,615) (15,960) Total net deferred tax assets 52,378 53,991 Deferred tax liabilities LIFO reserve (20,965) (25,913) Amortizable intangibles (52,952) (61,023) Goodwill (15,727) (13,902) Property, plant, equipment (38,175) (39,454) Lease right-of-use assets (14,103) (15,547) Investments (26,449) (16,353) Other (3,401) (5,590) Total deferred tax liabilities (171,772) (177,782) Deferred net long-term income tax liability $ (119,394) $ (123,791) 1 Certain amounts were reclassified between categories to conform to the current period presentation. At April 30, 2022, we had a U.S. foreign tax credit asset that will expire in four years. In addition, we have foreign deferred tax assets which would give rise to tax capital losses if triggered in the future. These losses can only be used against capital gain income. At this time, we believe that it is more likely than not that the foreign tax credit and potential capital loss carryforward attributes totaling $18,615 will not be fully utilized prior to expiration. As a result, a full valuation allowance has been established against these assets. With regard to unremitted earnings of foreign subsidiaries generated after December 31, 2017, we do not currently provide for U.S. taxes since we intend to reinvest such undistributed earnings indefinitely outside of the United States. Income tax expense (benefit) varies from the amount computed using the U.S. statutory rate. The reasons for this difference and the related tax effects are shown below. Fiscal Year Ended April 30, April 24, April 25, Tax at U.S. statutory rate $ 55,912 $ 41,984 $ (123,987) State tax provision, net of federal benefit 9,176 5,400 (466) Effect of foreign taxes 3,199 2,594 7,277 Goodwill impairment — — 107,999 Legal settlement — — 11,088 ESOP (2,121) (2,286) (2,393) Other permanent differences 944 808 1,533 Other (2,570) (3,678) (2,091) Income tax expense (benefit) $ 64,540 $ 44,822 $ (1,040) We have accounted for the uncertainty in income taxes recognized in the financial statements in accordance with ASC Topic 740. This standard clarifies the separate identification and reporting of estimated amounts that could be assessed upon audit. The potential assessments are considered unrecognized tax benefits, because, if it is ultimately determined they are unnecessary, the reversal of these previously recorded amounts will result in a beneficial impact to our financial statements. As of April 30, 2022 and April 24, 2021, Patterson’s gross unrecognized tax benefits were $9,898 and $10,866, respectively. If determined to be unnecessary, these amounts (net of deferred tax assets of $1,786 and $2,055, respectively, related to the tax deductibility of the gross liabilities) would decrease our effective tax rate. The gross unrecognized tax benefits are included in other non-current liabilities on the consolidated balance sheets. A summary of the changes in the gross amounts of unrecognized tax benefits is shown below. April 30, April 24, Balance at beginning of period $ 10,866 $ 11,740 Additions for tax positions related to the current year 1,001 1,264 Additions for tax positions of prior years 42 20 Reductions for tax positions of prior years (77) (220) Statute expirations (1,527) (1,938) Settlements (407) — Balance at end of period $ 9,898 $ 10,866 We also recognize both interest and penalties with respect to unrecognized tax benefits as a component of income tax expense. As of April 30, 2022 and April 24, 2021, we had recorded $1,583 and $2,026, respectively, for interest and penalties. These amounts are also included in other non-current liabilities on the consolidated balance sheets. These amounts, net of related deferred tax assets, if determined to be unnecessary, would decrease our effective tax rate. During the year ended April 30, 2022, we recorded as part of tax expense $229 related to an increase in our estimated liability for interest and penalties. Patterson files income tax returns, including returns for our subsidiaries, with federal, state, local and foreign jurisdictions. During fiscal 2021, the Internal Revenue Service (“IRS”) concluded an audit of the fiscal year ended

Technology Partner Innovations,

Technology Partner Innovations, LLC ("TPI")	12 Months Ended
	Apr. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Technology Partner Innovations, LLC ("TPI")	Technology Partner Innovations, LLC ("TPI")In fiscal 2019, we entered into an agreement with Cure Partners to form TPI, which offers a cloud-based practice management software, NaVetor, to its customers. Patterson and Cure Partners each contributed net assets of $4,000 to form TPI. We determined that TPI is a variable interest entity, and we consolidate the results of operations of TPI as we have concluded that we are the primary beneficiary of TPI. Patterson and Cure Partners each contributed additional net assets of $1,000 during fiscal 2022 to TPI. During fiscal 2022, 2021 and 2020, net loss attributable to the noncontrolling interest was $1,496, $872 and $921, respectively. Since TPI was formed, there have been no changes in ownership interests. As of April 30, 2022, we had noncontrolling interests of $959 on our consolidated balance sheets

Segment and Geographic Data

Segment and Geographic Data	12 Months Ended
	Apr. 30, 2022
Segment Reporting [Abstract]
Segment and Geographic Data	Segment and Geographic Data We present three reportable segments: Dental, Animal Health and Corporate. Dental and Animal Health are strategic business units that offer similar products and services to different customer bases. Dental provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists, dental laboratories, institutions, and other healthcare professionals throughout North America. Animal Health is a leading, full-line distributor in North America and the U.K. of animal health products, services and technologies to both the production-animal and companion-pet markets. Our Corporate segment is comprised of general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities. In addition, customer financing and other miscellaneous sales are reported within Corporate results. Corporate assets consist primarily of cash and cash equivalents, accounts receivable, property and equipment and long-term receivables. We evaluate segment performance based on operating income (loss). The costs to operate the fulfillment centers are allocated to the business units based on the through-put of the unit. The following tables present information about our reportable segments and the geographic areas in which we operate: Fiscal Year Ended April 30, April 24, April 25, Consolidated net sales United States $ 5,358,489 $ 4,877,070 $ 4,554,345 United Kingdom 717,481 677,910 608,320 Canada 423,435 357,086 327,346 Total $ 6,499,405 $ 5,912,066 $ 5,490,011 Dental net sales United States $ 2,259,579 $ 2,107,521 $ 1,900,539 Canada 256,553 219,500 201,383 Total $ 2,516,132 $ 2,327,021 $ 2,101,922 Animal Health net sales United States $ 3,098,511 $ 2,744,498 $ 2,601,970 United Kingdom 717,481 677,910 608,320 Canada 166,882 137,586 125,963 Total $ 3,982,874 $ 3,559,994 $ 3,336,253 Corporate net sales United States $ 399 $ 25,051 $ 51,836 Total $ 399 $ 25,051 $ 51,836 Fiscal Year Ended April 30, April 24, 2021 1 April 25, Consolidated net sales Consumable $ 5,248,040 $ 4,748,416 $ 4,374,829 Equipment and software 920,424 822,063 749,390 Value-added services and other 330,941 341,587 365,792 Total $ 6,499,405 $ 5,912,066 $ 5,490,011 Dental net sales Consumable $ 1,424,677 $ 1,314,236 $ 1,141,189 Equipment and software 800,144 730,928 677,677 Value-added services and other 291,311 281,857 283,056 Total $ 2,516,132 $ 2,327,021 $ 2,101,922 Animal Health net sales Consumable $ 3,823,363 $ 3,434,180 $ 3,233,640 Equipment and software 120,280 91,135 71,713 Value-added services and other 39,231 34,679 30,900 Total $ 3,982,874 $ 3,559,994 $ 3,336,253 Corporate net sales Value-added services and other $ 399 $ 25,051 $ 51,836 Total $ 399 $ 25,051 $ 51,836 1 Certain sales were reclassified between categories to conform to the current period presentation. Fiscal Year Ended April 30, April 24, April 25, Operating income (loss) Dental $ 180,212 $ 201,244 $ 168,304 Animal Health 114,403 88,123 (594,743) Corporate (137,613) (78,760) (145,680) Consolidated operating income (loss) $ 157,002 $ 210,607 $ (572,119) Depreciation and amortization Dental $ 13,495 $ 7,774 $ 8,434 Animal Health 44,561 45,771 49,958 Corporate 23,936 23,004 23,790 Consolidated depreciation and amortization $ 81,992 $ 76,549 $ 82,182 April 30, April 24, Property and equipment, net United States $ 200,839 $ 209,361 United Kingdom 6,045 2,471 Canada 6,256 7,606 Total property and equipment, net $ 213,140 $ 219,438 April 30, April 24, Total assets Dental $ 851,746 $ 863,718 Animal Health 1,459,450 1,391,892 Corporate 430,434 495,901 Total assets $ 2,741,630 $ 2,751,511

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Apr. 30, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Dividends The following table presents our declared cash dividends per share on our common stock for the past three years. In fiscal 2022 and 2021, dividends were declared in the period presented and paid in the following quarter. Dividends were declared and paid in the same period during fiscal 2020. Quarter Fiscal year 1 2 3 4 2022 $ 0.26 $ 0.26 $ 0.26 $ 0.26 2021 0.26 0.26 0.26 0.26 2020 0.26 0.26 0.26 0.26 Share Repurchases During fiscal 2022, we repurchased 1,032 shares of our common stock for $35,000, or an average of $33.90 per share. During fiscal 2021 and 2020, we had no repurchases of shares of our common stock. On March 16, 2021, the Board of Directors authorized a $500,000 share repurchase program through March 16, 2024. As of April 30, 2022, $465,000 remains available under the current repurchase authorization. ESOP In 1990, Patterson’s Board of Directors adopted a leveraged ESOP. In fiscal 1991, under the provisions of the plan and related financing arrangements, Patterson loaned the ESOP $22,000 (the “1990 note”) for the purpose of acquiring its then outstanding preferred stock, which was subsequently converted to common stock. The Board of Directors determines the contribution from the Company to the ESOP annually. The contribution is used to retire a portion of the debt, which triggers a release of shares that are then allocated to the employee participants. Shares of stock acquired by the plan are allocated to each participant who has completed 1000 hours of service during the plan year. In fiscal 2011, the final payment on the 1990 note was made and all remaining shares were released for allocation to participants. In fiscal 2002, Patterson’s ESOP and an ESOP sponsored by the Thompson Dental Company (“Thompson”) were used to facilitate the acquisition and merger of Thompson into Patterson. The net result of this transaction was an additional loan of $12,612 being made to the ESOP and the ESOP acquiring 666 shares of common stock. The loan bore interest at then-current rates, but principal did not begin to amortize until fiscal 2012. Beginning in fiscal 2012 and through fiscal 2020, an annual payment of $200 plus interest was due. In fiscal 2021, a final payment of the outstanding principal and interest balance was due and was made. Of the 666 shares issued in the transaction, 98 were previously allocated to Thompson employees. The remaining 568 shares began to be allocated in fiscal 2004 as interest was paid on the loan. In September 2006, we entered into a third loan agreement with the ESOP and loaned $105,000 (the “2006 note”) for the sole purpose of enabling the ESOP to purchase shares of our common stock. The ESOP purchased 3,160 shares with the proceeds from the 2006 note. Interest on the unpaid principal balance accrued at a rate equal to six-month LIBOR, with the rate resetting semi-annually. Interest payments were not required during the period from and including September 11, 2006 through April 30, 2010. On April 30, 2010, accrued and unpaid interest was added to the outstanding principal balance under the note, with interest thereafter accruing on the increased principal amount. Unpaid interest accruing after April 30, 2010 was due and payable on each successive April 30. In fiscal 2021, a final payment of the outstanding principal and interest balance was made. In fiscal 2012, Patterson contributed $20,214 to the ESOP, which then purchased 844 shares for allocation to the participants. No shares secured by the 2006 note were released prior to fiscal 2011. At April 30, 2022, a total of 9,551 shares of common stock that have been allocated to participants remained in the ESOP and had a fair market value of $293,879. As of April 30, 2022, there were no committed-to-be-released shares and no suspense shares remaining related to the ESOP. Unearned ESOP shares are not considered outstanding for the computation of earnings per share until the shares are committed for release to the participants. During fiscal 2022, 2021 and 2020, the compensation expense recognized related to the ESOP was $0, $9,265 and $14,419, respectively. This compensation expense was computed based on the shares allocated method. In fiscal 2021, we allocated the remaining suspense shares to eligible ESOP participants. We will recognize an income tax deduction on the unearned ESOP shares released. Such deductions will be limited to the ESOP’s original cost to acquire the shares. We will no longer be contributing to the ESOP after fiscal 2021, and instead we have and will be making cash-based 401(k) contributions. Dividends on allocated shares are passed through to the ESOP participants.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Apr. 30, 2022
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation The consolidated statements of operations and other comprehensive income (loss) for fiscal 2022, 2021 and 2020 include pre-tax (after-tax) stock-based compensation expense of $23,805 ($18,686), $21,223 ($16,387) and $22,935 ($17,789), respectively. Pre-tax expense is included in operating expenses within the consolidated statements of operations and other comprehensive income (loss). As of April 30, 2022, the total unrecognized compensation cost related to non-vested awards was $22,718, and it is expected to be recognized over a weighted average period of approximately 1.3 years. 2015 Omnibus Incentive Plan In September 2015, our shareholders approved the 2015 Omnibus Incentive Plan ("Incentive Plan"), which was most recently amended and restated in September 2021. The aggregate number of shares of common stock that may be issued is 19,500. The Incentive Plan authorizes various award types to be issued under the plan, including stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance awards, non-employee director awards, cash-based awards and other stock-based awards. We issue new shares for stock option exercises, restricted stock award grants and also for vesting of restricted stock units and performance stock units. Awards that expire or are canceled without delivery of shares generally become available for reissuance under the plan. At April 30, 2022, there were 10,515 shares available for awards under the Incentive Plan. As a result of the approval of the Incentive Plan, awards are no longer granted under any prior equity incentive plan, but all outstanding awards previously granted under such prior plans will remain outstanding and subject to the terms of such prior plans. At April 30, 2022, there were 307 shares outstanding under prior plans. Inducement Awards On June 29, 2018, we issued a combination of non-statutory stock options and restricted stock units outside our Incentive Plan to our Chief Financial Officer. The stock option covers 99 shares of our common stock, has an exercise price of $22.67 per share, and has a 10-year term. Such award vested to the extent of one-third of the award on the first anniversary of the date of grant, one-third of the award on the second anniversary of the date of grant, and the remaining one-third of the award on the third anniversary of the date of grant. The restricted stock unit award covers 31 shares of our common stock. Such award vested to the extent of 50% of the award on the first anniversary of the date of grant and the remaining 50% of the award on the second anniversary of the date of grant. Stock Option Awards Stock options granted to employees expire no later than ten years after the date of grant. Awards typically vest over three The fair value of stock options granted was estimated as of the grant date using a Black-Scholes option-pricing model with the following assumptions: Fiscal Year Ended April 30, April 24, April 25, Expected dividend yield 3.4 % 4.4 % 4.7 % Expected stock price volatility 38.1 % 34.6 % 26.8 % Risk-free interest rate 1.1 % 0.4 % 1.8 % Expected life (years) 6.0 6.0 6.0 Weighted average grant date fair value per share $ 7.97 $ 4.60 $ 3.37 The following is a summary of stock option activity: Number Weighted- Aggregate Intrinsic Balance as of April 24, 2021 2,697 $ 28.31 Granted 290 30.74 Exercised (175) 22.76 Canceled (75) 43.01 Balance as of April 30, 2022 2,737 $ 28.52 $ 15,615 Vested or expected to vest as of April 30, 2022 2,727 $ 28.53 $ 15,557 Exercisable as of April 30, 2022 1,707 $ 30.39 $ 9,858 The weighted average remaining contractual lives of options outstanding and options exercisable as of April 30, 2022 were 6.8 and 6.0 years, respectively. Related to stock options exercised, the intrinsic value, cash received and tax benefits realized were $1,552, $3,975 and $238, respectively, in fiscal 2022; and $953, $3,399 and $129, respectively, in fiscal 2021. No stock options were exercised in fiscal 2020. Restricted Stock Restricted stock awards and restricted stock units granted to employees generally vest over a three five The following is a summary of restricted stock award activity: Restricted Stock Awards Shares Weighted- Outstanding at April 24, 2021 54 $ 30.63 Granted 32 31.86 Vested (53) 30.45 Forfeitures (6) 33.29 Outstanding at April 30, 2022 27 $ 31.86 The following is a summary of restricted stock unit activity: Restricted Stock Units Shares Weighted- Outstanding at April 24, 2021 1,241 $ 25.65 Granted 417 30.79 Vested (586) 26.42 Forfeitures (70) 26.92 Outstanding at April 30, 2022 1,002 $ 27.24 Performance Unit Awards In fiscal 2022, 2021 and 2020, we granted performance unit awards to certain executives which are earned at the end of a three three The following is a summary of performance unit award activity at target: Performance Unit Awards Shares Weighted- Outstanding at April 24, 2021 288 $ 22.94 Granted 150 29.67 Vested — — Forfeitures and cancellations — — Outstanding at April 30, 2022 438 $ 26.14 Employee Stock Purchase Plan ("ESPP") We sponsor an ESPP under which a total of 9,000 shares have been reserved for purchase by employees. Eligible employees may purchase shares at 85% of the lower of the fair market value of our common stock on the beginning of the annual offering period, or on the end of each quarterly purchase period, which occur on March 31, June 30, September 30 and December 31. The offering periods begin on January 1 of each calendar year and end on December 31 of each calendar year. At April 30, 2022, there were 1,387 shares available for purchase under the ESPP. We estimate the grant date fair value of shares purchased under our ESPP using the Black-Scholes option pricing valuation model with the following assumptions: Fiscal Year Ended April 30, April 24, April 25, Expected dividend yield 3.6 % 3.6 % 5.1 % Expected stock price volatility 28.6 % 51.7 % 34.3 % Risk-free interest rate 0.3 % 0.1 % 1.6 % Expected life (years) 0.6 0.6 0.6 Weighted average grant date fair value per share $ 6.79 $ 8.77 $ 4.98

Litigation

Litigation	12 Months Ended
	Apr. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Litigation	Litigation From time to time, we become involved in lawsuits, administrative proceedings, government subpoenas, and government investigations (which may, in some cases, involve our entering into settlement agreements or consent decrees), relating to antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, securities, and other matters, including matters arising out of the ordinary course of business. The results of any such proceedings cannot be predicted with certainty because such matters are inherently uncertain. Significant damages or penalties may be sought in some matters, and some matters may require years to resolve. We also may be subject to fines or penalties, and equitable remedies (including but not limited to the suspension, revocation or non-renewal of licenses). We accrue for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Unless otherwise noted, with respect to the specific legal proceedings and claims described below, the amount or range or possible losses is not reasonably estimable. Adverse outcomes in some or all of these matters may result in significant monetary damages or injunctive relief against us that could adversely affect our ability to conduct our business. There also exists the possibility of a material adverse effect on our financial statements for the period in which the effect of an unfavorable outcome becomes probable and reasonably estimable. On March 28, 2018, Plymouth County Retirement System (“Plymouth”) filed a federal securities class action complaint against Patterson Companies, Inc. and its former CEO Scott P. Anderson and former CFO Ann B. Gugino in the U.S. District Court for the District of Minnesota in a case captioned Plymouth County Retirement System v. Patterson Companies, Inc., Scott P. Anderson and Ann B. Gugino, Case No. 0:18-cv-00871 MJD/SER. On November 9, 2018, the complaint was amended to add former CEO James W. Wiltz and former CFO R. Stephen Armstrong as individual defendants. Under the amended complaint, on behalf of all persons or entities that purchased or otherwise acquired Patterson’s common stock between June 26, 2013 and February 28, 2018, Plymouth alleges that Patterson violated federal securities laws by failing to disclose that Patterson’s revenue and earnings were “artificially inflated by Defendants’ illicit, anti-competitive scheme with its purported competitors, Benco and Schein, to prevent the formation of buying groups that would allow its customers who were office-based practitioners to take advantage of pricing arrangements identical or comparable to those enjoyed by large-group customers.” In its class action complaint, Plymouth asserts one count against Patterson for violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and a second, related count against the individual defendants for violating Section 20(a) of the Exchange Act. Plymouth seeks compensatory damages, pre- and post-judgment interest and reasonable attorneys’ fees and experts’ witness fees and costs. On August 30, 2018, Gwinnett County Public Employees Retirement System and Plymouth County Retirement System, Pembroke Pines Pension Fund for Firefighters and Police Officers, Central Laborers Pension Fund were appointed lead plaintiffs. On January 18, 2019, Patterson and the individual defendants filed a motion to dismiss the amended complaint. On July 25, 2019, the U.S. Magistrate Judge issued a report and recommendation that the motion to dismiss be granted in part and denied in part. The report and recommendation, among other things, recommends the dismissal of all claims against individual defendants Ann B. Gugino, R. Stephen Armstrong and James W. Wiltz. On September 10, 2019, the District Court adopted the Magistrate Judge’s report and recommendation. On September 28, 2020, the District Court granted plaintiffs’ motion to certify the class, appoint class representatives and appoint class counsel. On October 12, 2020, Patterson and the remaining individual defendant, Mr. Anderson, filed a Rule 23(f) petition for interlocutory appeal of the class certification order with the Eighth Circuit Court of Appeals in which the defendants sought clarification of the standard for rebutting the Basic presumption of class-wide reliance in securities class actions. On October 13, 2020, Patterson and Mr. Anderson filed a motion to stay the underlying proceeding with the District Court pending the possibility of interlocutory appeal. On November 9, 2020, the District Court denied defendants’ motion to stay and on November 12, 2020, the Eighth Circuit Court of Appeals denied defendants’ Rule 23(f) petition. On May 17, 2021, Patterson and Mr. Anderson filed a motion for

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss ("AOCL")	12 Months Ended
	Apr. 30, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss (AOCL)	Accumulated Other Comprehensive Loss ("AOCL") The following table summarizes the changes in AOCL as of April 30, 2022: Cash Flow Currency Total AOCL at April 24, 2021 $ (4,496) $ (58,096) $ (62,592) Other comprehensive income before reclassifications — (19,966) (19,966) Amounts reclassified from AOCL 1,042 — 1,042 AOCL at April 30, 2022 $ (3,454) $ (78,062) $ (81,516) The amounts reclassified from AOCL during fiscal 2022 represent gains and losses on cash flow hedges, net of taxes of $321. The impact to the consolidated statements of operations and other comprehensive income (loss) was an increase to interest expense of $1,363 for fiscal 2022.

Schedule II Valuation And Quali

Schedule II Valuation And Qualifying Accounts	12 Months Ended
	Apr. 30, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II Valuation And Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS PATTERSON COMPANIES, INC. (In thousands) Balance at Charged to Charged Deductions Balance at Year ended April 30, 2022 Deducted from asset accounts: Allowance for doubtful accounts $ 6,138 $ 2,769 $ — $ 2,994 $ 5,913 LIFO inventory adjustment $ 120,775 $ 10,184 $ — $ — $ 130,959 Inventory obsolescence reserve 29,629 61,647 — 69,733 21,543 Total inventory reserve $ 150,404 $ 71,831 $ — $ 69,733 $ 152,502 Year ended April 24, 2021 Deducted from asset accounts: Allowance for doubtful accounts $ 5,123 $ 2,559 $ — $ 1,544 $ 6,138 LIFO inventory adjustment $ 99,726 $ 21,049 $ — $ — $ 120,775 Inventory obsolescence reserve 25,526 45,761 — 41,658 29,629 Total inventory reserve $ 125,252 $ 66,810 $ — $ 41,658 $ 150,404 Year ended April 25, 2020 Deducted from asset accounts: Allowance for doubtful accounts $ 6,772 $ 2,008 $ — $ 3,657 $ 5,123 LIFO inventory adjustment $ 91,342 $ 8,384 $ — $ — $ 99,726 Inventory obsolescence reserve 10,099 27,405 — 11,978 25,526 Total inventory reserve $ 101,441 $ 35,789 $ — $ 11,978 $ 125,252

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Apr. 30, 2022
Accounting Policies [Abstract]
Description of Business	Description of Business Patterson Companies, Inc. (referred to herein as “Patterson” or in the first person notations “we,” “our,” and “us”) is a value-added specialty distributor serving the U.S. and Canadian dental supply and the U.S., Canadian and U.K. animal health supply markets. Patterson has three reportable segments: Dental, Animal Health and Corporate.
Basis of Presentation	Basis of Presentation The consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding"), PDC Funding Company II, LLC ("PDC Funding II"), PDC Funding Company III, LLC ("PDC Funding III") and PDC Funding Company IV, LLC ("PDC Funding IV") , which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. PDC Funding III and PDC Funding IV are fully consolidated special purpose entity established to sell certain receivables to unaffiliated financial institutions. The assets of PDC Funding, PDC Funding II, PDC Funding III and PDC Funding IV would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding, PDC Funding II, PDC Funding III or PDC Funding IV. The consolidated financial statements also include the assets and liabilities of Technology Partner Innovations, LLC, which is further described in Note 13.
Fiscal Year End	Fiscal Year End We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. Fiscal 2022 ended on April 30, 2022 and consisted of 53 weeks. Fiscal 2021 and 2020 ended on April 24, 2021 and April 25, 2020, respectively, and both consisted of 52 weeks. Fiscal 2023 will end on April 29, 2023 and will consist of 52 weeks.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash equivalents consist primarily of investments in money market funds and government securities. The maturity of these securities at the time of purchase is 90 days or less. All cash and cash equivalents are classified as available-for-sale and carried at fair value, which approximates cost.
Inventory	InventoryInventory consists of merchandise held for sale and is stated at the lower of cost or market. The cost of our inventory includes the amount we pay to our suppliers to acquire inventory and freight costs incurred in connection with the delivery of product to our distribution centers and our other locations. Cost is determined using the last-in, first-out ("LIFO") method for all inventories, except for foreign inventories, which are valued using the first-in, first-out ("FIFO") method. Inventories valued at LIFO represented 85% and 83% of total inventories at April 30, 2022 and April 24, 2021, respectively.
Property and Equipment	Property and EquipmentProperty and equipment are stated at cost. Depreciation is calculated on the straight-line method over estimated useful lives of up to 39 years for buildings or the expected remaining life of purchased buildings, the term of the lease for leasehold improvements, 3 to 10 years for computer hardware and software, and 5 to 10 years for furniture and equipment.
Goodwill and Other Indefinite-Lived Intangible Assets	Goodwill and Other Indefinite-Lived Intangible Assets Goodwill represents the excess of cost over the fair value of identifiable net assets of businesses acquired. Impairment testing for goodwill is done at the reporting unit level, with all goodwill assigned to a reporting unit. We have two reporting units as of April 30, 2022; Dental and Animal Health. Our Corporate reportable segment's assets and liabilities, and net sales and expenses, are allocated to the two reporting units. We assess goodwill for impairment annually and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Any goodwill impairment is measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. The determination of fair value involves uncertainties because it requires management to make assumptions and to apply judgment to estimate industry and economic factors and the profitability of future business strategies. Patterson conducts impairment testing based on current business strategy in light of present industry and economic conditions, as well as future expectations. Additionally, in assessing goodwill for impairment, the reasonableness of the implied control premium is considered based on market capitalizations and recent market transactions. Our indefinite-lived intangible asset is a trade name, which is assessed for impairment by comparing the carrying value of the asset with its fair value. If the carrying value exceeds fair value, an impairment loss is recognized in an amount equal to the excess. The determination of fair value involves assumptions, including projected revenues and gross profit levels, as well as consideration of any factors that may indicate potential impairment. In connection with the preparation of these financial statements in the fourth quarter of fiscal 2022, management completed its annual goodwill and other indefinite-lived intangible asset impairment tests using the beginning of our fiscal 2022 fourth quarter as the valuation date. We determined that there was no impairment of either goodwill or our indefinite-lived intangible asset. In connection with the preparation of our fiscal 2021 Form 10-K in the fourth quarter of fiscal 2021, management completed its annual goodwill and other indefinite-lived intangible asset impairment tests using the beginning of our fiscal 2021 fourth quarter as the valuation date. We determined that there was no impairment of either goodwill or our indefinite-lived intangible asset. In connection with the preparation of our fiscal 2020 Form 10-K in the fourth quarter of fiscal 2020, management completed its annual goodwill and other indefinite-lived intangible asset impairment tests using the beginning of our fiscal 2020 fourth quarter as the valuation date. We determined that there was no impairment of our indefinite-lived intangible asset. Our annual goodwill impairment test resulted in no impairment to the Dental reporting unit’s goodwill, and a $269,000 non-cash pre-tax impairment charge of our Animal Health reporting unit’s goodwill. The decrease in the fair value of the Animal Health reporting unit below its carrying value was mainly the result of a reduction in management’s estimates of future cash flows. Future cash flows were affected by a reduction in future sales volume and operating margins. The sales volume estimate reflected recent sales trends we had experienced. Future operating margins are expected to be lower based on then-current trends in our markets. These trends were driven by customer and vendor consolidation. Subsequent to the annual test being completed and in connection with the preparation of our fiscal 2020 Form 10-K in the fourth quarter of fiscal 2020, we experienced events and circumstances that indicated that the carrying amount of goodwill may have been further impaired. These events and circumstances included a decline in our projected future earnings and a sustained decrease in our share price. As such, we tested our goodwill for impairment as of the beginning of our fiscal April 2020. This test resulted in no impairment to the Dental reporting unit’s goodwill, and a $406,055 non-cash pre-tax impairment charge of our Animal Health reporting unit’s goodwill. The decrease in the fair value of the Animal Health reporting unit subsequent to the annual goodwill impairment test was caused by additional reductions in management’s estimates of future cash flows, driven by reduced sales volumes, as well as reduced EBITDA multiples of comparable companies. These estimates and market multiples were negatively affected by COVID-19. In fiscal 2020, the animal health industry experienced a reduction in sales volume as a result of stay at home and shelter in place orders, as well as a result of meat packing plant closures. Our future cash flow estimates for this business unit in fiscal 2020 reflected the long-term impact of COVID-19.
Long-Lived Assets	Long-Lived AssetsLong-lived assets, including definite-lived intangible assets, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. Our definite-lived intangible assets primarily consist of customer relationships, trade names and trademarks. When impairment exists, the related assets are written down to fair value using level 3 inputs, as discussed further in Note 7.
Financial Instruments	Financial Instruments We account for derivative financial instruments under the provisions of Accounting Standards Codification ("ASC") Topic 815, “Derivatives and Hedging.” Our use of derivative financial instruments is generally limited to managing well-defined interest rate risks. We do not use financial instruments or derivatives for any trading purposes.
Revenue Recognition and Contract Balances	Revenue Recognition Revenues are generated from the sale of consumable products, equipment and support, software and support, technical service parts and labor, and other sources. Revenues are recognized when or as performance obligations are satisfied. Performance obligations are satisfied when the customer obtains control of the goods or services. Consumable, equipment, software and parts sales are recorded upon delivery, except in those circumstances where terms of the sale are FOB shipping point, in which case sales are recorded upon shipment. Technical service labor is recognized as it is provided. Revenue derived from equipment and software support is recognized ratably over the period in which the support is provided. In addition to revenues generated from the distribution of consumable products under arrangements (buy/sell agreements) where the full market value of the product is recorded as revenue, we earn commissions for services provided under agency agreements. The agency agreement contrasts to a buy/sell agreement in that we do not have control over the transaction, as we do not have the primary responsibility of fulfilling the promise of the good or service and we do not bill or collect from the customer in an agency relationship. Commissions under agency agreements are recorded when the services are provided. Estimates for returns, damaged goods, rebates, loyalty programs and other revenue allowances are made at the time the revenue is recognized based on the historical experience for such items. The receivables that result from the recognition of revenue are reported net of related allowances. We maintain a valuation allowance based upon the expected collectability of receivables held. Estimates are used to determine the valuation allowance and are based on several factors, including historical collection data, economic trends and credit worthiness of customers. Receivables are written off when we determine the amounts to be uncollectible, typically upon customer bankruptcy or non-response to continuous collection efforts. The portions of receivable amounts that are not expected to be collected during the next twelve months are classified as long-term. Patterson has a relatively large, dispersed customer base and no single customer accounts for more than 10% of consolidated net sales. In addition, the equipment sold to customers under finance contracts generally serves as collateral for the contract and the customer provides a personal guarantee as well. Net sales do not include sales tax as we are considered a pass-through conduit for collecting and remitting sales tax. Contract Balances Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities.
Patterson Advantage Loyalty Program	Patterson Advantage Loyalty Program The Dental segment provides a point-based awards program to qualifying customers involving the issuance of “Patterson Advantage dollars” which can be used toward equipment and technology purchases. Patterson Advantage dollars earned during a program year expire one year after the end of the program year. The cost and corresponding liability associated with the program are recognized as contra-revenue. As of April 30, 2022, we believe we have sufficient experience with the program to reasonably estimate the amount of Patterson Advantage dollars that will not be redeemed and thus have recorded a liability for 88.0% of the maximum potential amount that could be redeemed. We recognize the expected breakage amount as revenue in proportion to the pattern of rights exercised by the customer, and we recognize the estimated value of unused Patterson Advantage dollars as redemptions occur. Breakage recognized was immaterial to all periods presented.
Freight and Delivery Charges	Freight and Delivery Charges Freight and delivery charges are included in cost of sales in the consolidated statements of operations and other comprehensive income (loss).
Advertising	AdvertisingWe expense all advertising and promotional costs as incurred, except for direct marketing expenses, which are expensed over the shorter of the life of the asset or one year.
Income Taxes	ncome Taxes The liability method is used to account for income tax expense. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established for deferred tax assets if, after assessment of available positive and negative evidence, it is more likely than not that the deferred tax asset will not be fully realized.
Self-insurance	Self-insurance Patterson is self-insured for certain losses related to general liability, product liability, automobile, workers’ compensation and medical claims. We estimate our liabilities based upon an analysis of historical data and actuarial estimates. While current estimates are believed reasonable based on information currently available, actual results could differ and affect financial results due to changes in the amount or frequency of claims, medical cost inflation or other factors. Historically, actual results related to these types of claims have not varied significantly from estimated amounts.
Stock-based Compensation	Stock-based Compensation We recognize stock-based compensation expense based on estimated grant date fair values. The grant date fair value of stock options and stock purchases made through our Employee Stock Purchase Plan are estimated using the Black-Scholes option pricing valuation model. The grant date fair value of performance stock units that vest upon meeting certain market conditions is estimated using the Monte Carlo valuation model. These valuations require estimates to be made including expected stock price volatility which considers historical volatility trends, implied future volatility based on certain traded options and other factors. We estimate the expected life of awards based on several factors, including types of participants, vesting schedules, contractual terms and various factors surrounding exercise behavior of different groups. The grant date fair value of time-based restricted stock awards and restricted stock units is calculated based on the closing price of our common stock on the date of grant.
Comprehensive Income	Comprehensive Income (Loss)Comprehensive income (loss) is computed as net income (loss) plus certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income (loss) are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S.
Earnings Per Share	Earnings (Loss) Per Share ("EPS") The amount of basic EPS is computed by dividing net income (loss) attributable to Patterson Companies, Inc. by the weighted average number of outstanding common shares during the period. The amount of diluted EPS is computed by dividing net income (loss) by the weighted average number of outstanding common shares and common share equivalents, when dilutive, during the period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” in March 2020 and ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope” in January 2021. These ASUs provide temporary optional expedients and exceptions to existing guidance on contract modifications and hedge accounting to facilitate the market transition from existing reference rates, such as LIBOR which began to be phased out at the end of 2021, to alternate reference rates. These standards were effective upon issuance. We are evaluating the optional relief guidance provided within these ASUs, and are reviewing our debt securities, derivative instruments and customer financing contracts that currently utilize LIBOR as the reference rate.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Apr. 30, 2022
Accounting Policies [Abstract]
Schedule of Other Non-current Assets	Other Non-current Assets, Net April 30, 2022 April 24, 2021 Development costs of software to be sold, net $ 64,513 $ 68,156 Other 42,995 21,703 Other non-current assets, net $ 107,508 $ 89,859
Schedule of Other Income, Net	Other Income (Expense), Net Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Gain (loss) on interest rate swap agreements $ 15,835 $ 1,151 $ (18,712) Investment income and other 11,896 12,457 7,877 Other income (expense), net $ 27,731 $ 13,608 $ (10,835)
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the denominator for the computation of basic and diluted EPS. There were no material adjustments to the numerator. Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Denominator for basic EPS – weighted average shares 97,277 95,599 94,154 Effect of dilutive securities – stock options, restricted stock and stock purchase plans 1,237 1,065 — Denominator for diluted EPS – weighted average shares 98,514 96,664 94,154

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Apr. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Cash and cash equivalents consisted of the following: April 30, 2022 April 24, 2021 Cash on hand $ 138,828 $ 141,546 Money market funds 3,186 1,698 Total $ 142,014 $ 143,244

Receivables Securitization Pr_2

Receivables Securitization Program (Tables)	12 Months Ended
	Apr. 30, 2022
Transfers and Servicing [Abstract]
Schedule of Deferred Purchase Price Receivable	The following summarizes the activity related to the DPP receivable: Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Beginning DPP receivable balance $ 183,999 $ 117,327 $ 57,238 Non-cash additions to DPP receivable 1,052,938 768,619 552,751 Cash collections on DPP receivable (1,041,173) (701,947) (492,662) Ending DPP receivable balance $ 195,764 $ 183,999 $ 117,327

Customer Financing (Tables)

Customer Financing (Tables)	12 Months Ended
	Apr. 30, 2022
Receivables [Abstract]
Rollforward Summary of Activity Related to the DPP Receivable	The following summarizes the activity related to the DPP receivable: Fiscal Year Ended April 30, 2022 April 24, 2021 April 25, 2020 Beginning DPP receivable balance $ 227,967 $ 228,019 $ 121,657 Non-cash additions to DPP receivable 69,689 131,959 154,644 Cash collections on DPP receivable (172,324) (132,011) (48,282) Ending DPP receivable balance $ 125,332 $ 227,967 $ 228,019

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Apr. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value of Derivative Instruments Included in Consolidated Balance Sheets	The following presents the fair value of derivative instruments included in the consolidated balance sheets: Derivative type Classification April 30, 2022 April 24, 2021 Assets: Interest rate contracts Prepaid expenses and other current assets $ 3,875 $ — Interest rate contracts Other non-current assets 19,871 2,120 Total asset derivatives $ 23,746 $ 2,120 Liabilities: Interest rate contracts Other accrued liabilities $ 250 $ 3,776 Interest rate contracts Other non-current liabilities 10,013 7,795 Total liability derivatives $ 10,263 $ 11,571
Effect of Derivative Instruments in Cash Flow Hedging Relationships on the Consolidated Statements of Income and Other Comprehensive Income	The following tables present the pre-tax effect of derivative instruments on the consolidated statements of operations and other comprehensive income (loss): Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion) Fiscal Year Ended Derivatives in cash flow hedging relationships Statements of operations April 30, 2022 April 24, 2021 April 25, 2020 Interest rate contracts Interest expense $ (1,363) $ (1,363) $ (10,458) Amount of Gain (Loss) Recognized in Income on Derivatives Fiscal Year Ended Derivatives not designated as hedging instruments Statements of operations April 30, 2022 April 24, 2021 April 25, 2020 Interest rate contracts Other income, net $ 15,835 $ 1,151 $ (18,712)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Apr. 30, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows: April 30, 2022 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 3,186 $ 3,186 $ — $ — DPP receivable - receivables securitization program 195,764 — — 195,764 DPP receivable - customer financing 125,332 — — 125,332 Derivative instruments 23,746 — 23,746 — Total assets $ 348,028 $ 3,186 $ 23,746 $ 321,096 Liabilities: Derivative instruments $ 10,263 $ — $ 10,263 $ — April 24, 2021 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 1,698 $ 1,698 $ — $ — DPP receivable - receivables securitization program 183,999 — — 183,999 DPP receivable - customer financing 227,967 — — 227,967 Derivative instruments 2,120 — 2,120 — Total assets $ 415,784 $ 1,698 $ 2,120 $ 411,966 Liabilities: Derivative instruments $ 11,571 $ — $ 11,571 $ —

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Apr. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Value of Goodwill	The changes in the carrying value of goodwill for each of our reportable segments for the fiscal year ended April 30, 2022 were as follows: Balance at April 24, 2021 Acquisition Foreign Currency Translation Balance at April 30, 2022 Dental $ 139,932 $ — $ (299) $ 139,633 Animal Health — 997 — 997 Corporate — — — — Total $ 139,932 $ 997 $ (299) $ 140,630
Balances of Other Intangible Assets Excluding Goodwill	Balances of other intangible assets, excluding goodwill, were as follows: April 30, 2022 April 24, 2021 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Unamortized - indefinite lived: Trade name $ 12,300 $ — $ 12,300 $ 12,300 $ — $ 12,300 Amortized - definite lived: Customer relationships 366,969 181,280 185,689 355,685 159,376 196,309 Trade names and trademarks 132,996 95,903 37,093 133,834 85,221 48,613 Developed technology and other 65,757 48,225 17,532 72,398 49,976 22,422 Total amortized intangible assets 565,722 325,408 240,314 561,917 294,573 267,344 Total identifiable intangible assets $ 578,022 $ 325,408 $ 252,614 $ 574,217 $ 294,573 $ 279,644

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Apr. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: April 30, 2022 April 24, 2021 Land $ 11,341 $ 12,014 Buildings 106,957 118,582 Leasehold improvements 31,395 31,125 Furniture and equipment 187,093 188,594 Computer hardware and software 254,205 244,537 Construction-in-progress (1) 30,502 17,665 Property and equipment, gross 621,493 612,517 Accumulated depreciation (408,353) (393,079) Property and equipment, net $ 213,140 $ 219,438 (1) Includes $8,585 and $6,326 of unamortized development costs of software to be sold as of April 30, 2022 and April 24, 2021, respectively.

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
	Apr. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Future Maturities of Lease Liabilities	The following table presents future maturities of lease liabilities: 2023 $ 31,165 2024 21,793 2025 12,650 2026 6,168 2027 2,941 After 2027 1,222 Total lease payments 75,939 Less: imputed interest (3,259) Present value of lease liabilities $ 72,680
Supplemental Information Related to Leases	The following tables present other supplemental information related to leases: Fiscal Year Ended April 30, 2022 April 24, 2021 Cash paid for amounts included in the measurement of operating lease liabilities $ 38,192 $ 37,054 Lease assets obtained in exchange for new operating lease liabilities $ 31,132 $ 50,114 April 30, 2022 April 24, 2021 Weighted-average remaining lease term - operating leases 2.98 years 3.06 years Weighted-average discount rate - operating leases 3.10 % 3.31 %

Debt (Tables)

Debt (Tables)	12 Months Ended
	Apr. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Our long-term debt consisted of the following: Carrying Value Interest Rate April 30, 2022 April 24, 2021 Senior notes due fiscal 2022 (1) 3.59 % $ — $ 100,750 Senior notes due fiscal 2024 (1) 3.74 % 33,000 33,000 Senior notes due fiscal 2025 (2) 3.48 % 117,500 117,500 Senior notes due fiscal 2028 (3) 3.79 % 40,000 40,000 Term loan due fiscal 2024 (4) 1.89 % 300,000 300,000 Less: Deferred debt issuance costs (1,946) (2,955) Total debt 488,554 588,295 Less: Current maturities of long-term debt — (100,750) Long-term debt $ 488,554 $ 487,545 (1) Issued in December 2011. (2) Issued in March 2015. (3) Issued in March 2018. (4) Issued in December 2019, amended in February 2021. Interest rate is 1-month LIBOR plus 1.13% as of April 30, 2022.
Schedule of Maturities of Long-term Debt	Future principal payments due, based on stated contractual maturities for our long-term debt, were as follows as of April 30, 2022: Fiscal Year 2023 $ — 2024 333,000 2025 117,500 2026 — 2027 — Thereafter 40,000 Total $ 490,500

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Apr. 30, 2022
Income Tax Disclosure [Abstract]
Components of Provision for Income Taxes	The components of income (loss) before taxes were as follows: Fiscal Year Ended April 30, April 24, April 25, Income (loss) before taxes United States $ 225,195 $ 166,251 $ (594,431) International 41,059 33,680 4,024 Total $ 266,254 $ 199,931 $ (590,407) Significant components of income tax expense (benefit) were as follows: Fiscal Year Ended April 30, April 24, April 25, Current: Federal $ 46,964 $ 36,836 $ 18,300 Foreign 11,968 9,975 7,501 State 10,326 8,771 4,959 Total current expense 69,258 55,582 30,760 Deferred: Federal (3,918) (7,529) (25,918) Foreign (217) (362) 164 State (583) (2,869) (6,046) Total deferred benefit (4,718) (10,760) (31,800) Income tax expense (benefit) $ 64,540 $ 44,822 $ (1,040)
Components of Deferred Tax Assets (Liabilities)	Significant components of our deferred tax assets (liabilities) were as follows: April 30, April 24, 2021 1 Deferred tax assets: Employee compensation and benefits $ 9,352 $ 12,223 Inventory related items 9,985 12,250 Foreign deferred assets, net 11,812 9,510 Foreign tax credit 7,037 7,112 Lease liability 14,416 16,153 Accrued charitable contributions 6,559 — Other accrued liabilities 6,642 7,331 Other 5,190 5,372 Gross deferred tax assets 70,993 69,951 Less: Valuation allowance (18,615) (15,960) Total net deferred tax assets 52,378 53,991 Deferred tax liabilities LIFO reserve (20,965) (25,913) Amortizable intangibles (52,952) (61,023) Goodwill (15,727) (13,902) Property, plant, equipment (38,175) (39,454) Lease right-of-use assets (14,103) (15,547) Investments (26,449) (16,353) Other (3,401) (5,590) Total deferred tax liabilities (171,772) (177,782) Deferred net long-term income tax liability $ (119,394) $ (123,791)
Summary of Effective Income Tax Expense Reconciliation	Income tax expense (benefit) varies from the amount computed using the U.S. statutory rate. The reasons for this difference and the related tax effects are shown below. Fiscal Year Ended April 30, April 24, April 25, Tax at U.S. statutory rate $ 55,912 $ 41,984 $ (123,987) State tax provision, net of federal benefit 9,176 5,400 (466) Effect of foreign taxes 3,199 2,594 7,277 Goodwill impairment — — 107,999 Legal settlement — — 11,088 ESOP (2,121) (2,286) (2,393) Other permanent differences 944 808 1,533 Other (2,570) (3,678) (2,091) Income tax expense (benefit) $ 64,540 $ 44,822 $ (1,040)
Summary of Changes in Gross Amounts of Unrecognized Tax Benefits	A summary of the changes in the gross amounts of unrecognized tax benefits is shown below. April 30, April 24, Balance at beginning of period $ 10,866 $ 11,740 Additions for tax positions related to the current year 1,001 1,264 Additions for tax positions of prior years 42 20 Reductions for tax positions of prior years (77) (220) Statute expirations (1,527) (1,938) Settlements (407) — Balance at end of period $ 9,898 $ 10,866

Segment and Geographic Data (Ta

Segment and Geographic Data (Tables)	12 Months Ended
	Apr. 30, 2022
Segment Reporting [Abstract]
Information about Reportable Segments	The following tables present information about our reportable segments and the geographic areas in which we operate: Fiscal Year Ended April 30, April 24, April 25, Consolidated net sales United States $ 5,358,489 $ 4,877,070 $ 4,554,345 United Kingdom 717,481 677,910 608,320 Canada 423,435 357,086 327,346 Total $ 6,499,405 $ 5,912,066 $ 5,490,011 Dental net sales United States $ 2,259,579 $ 2,107,521 $ 1,900,539 Canada 256,553 219,500 201,383 Total $ 2,516,132 $ 2,327,021 $ 2,101,922 Animal Health net sales United States $ 3,098,511 $ 2,744,498 $ 2,601,970 United Kingdom 717,481 677,910 608,320 Canada 166,882 137,586 125,963 Total $ 3,982,874 $ 3,559,994 $ 3,336,253 Corporate net sales United States $ 399 $ 25,051 $ 51,836 Total $ 399 $ 25,051 $ 51,836 Fiscal Year Ended April 30, April 24, 2021 1 April 25, Consolidated net sales Consumable $ 5,248,040 $ 4,748,416 $ 4,374,829 Equipment and software 920,424 822,063 749,390 Value-added services and other 330,941 341,587 365,792 Total $ 6,499,405 $ 5,912,066 $ 5,490,011 Dental net sales Consumable $ 1,424,677 $ 1,314,236 $ 1,141,189 Equipment and software 800,144 730,928 677,677 Value-added services and other 291,311 281,857 283,056 Total $ 2,516,132 $ 2,327,021 $ 2,101,922 Animal Health net sales Consumable $ 3,823,363 $ 3,434,180 $ 3,233,640 Equipment and software 120,280 91,135 71,713 Value-added services and other 39,231 34,679 30,900 Total $ 3,982,874 $ 3,559,994 $ 3,336,253 Corporate net sales Value-added services and other $ 399 $ 25,051 $ 51,836 Total $ 399 $ 25,051 $ 51,836 1 Certain sales were reclassified between categories to conform to the current period presentation. Fiscal Year Ended April 30, April 24, April 25, Operating income (loss) Dental $ 180,212 $ 201,244 $ 168,304 Animal Health 114,403 88,123 (594,743) Corporate (137,613) (78,760) (145,680) Consolidated operating income (loss) $ 157,002 $ 210,607 $ (572,119) Depreciation and amortization Dental $ 13,495 $ 7,774 $ 8,434 Animal Health 44,561 45,771 49,958 Corporate 23,936 23,004 23,790 Consolidated depreciation and amortization $ 81,992 $ 76,549 $ 82,182
Information by Geographical Area	April 30, April 24, Property and equipment, net United States $ 200,839 $ 209,361 United Kingdom 6,045 2,471 Canada 6,256 7,606 Total property and equipment, net $ 213,140 $ 219,438 April 30, April 24, Total assets Dental $ 851,746 $ 863,718 Animal Health 1,459,450 1,391,892 Corporate 430,434 495,901 Total assets $ 2,741,630 $ 2,751,511

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Apr. 30, 2022
Equity [Abstract]
Cash Dividends Declared and Paid	The following table presents our declared cash dividends per share on our common stock for the past three years. In fiscal 2022 and 2021, dividends were declared in the period presented and paid in the following quarter. Dividends were declared and paid in the same period during fiscal 2020. Quarter Fiscal year 1 2 3 4 2022 $ 0.26 $ 0.26 $ 0.26 $ 0.26 2021 0.26 0.26 0.26 0.26 2020 0.26 0.26 0.26 0.26

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Apr. 30, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock Options, Weighted Average Assumptions	The fair value of stock options granted was estimated as of the grant date using a Black-Scholes option-pricing model with the following assumptions: Fiscal Year Ended April 30, April 24, April 25, Expected dividend yield 3.4 % 4.4 % 4.7 % Expected stock price volatility 38.1 % 34.6 % 26.8 % Risk-free interest rate 1.1 % 0.4 % 1.8 % Expected life (years) 6.0 6.0 6.0 Weighted average grant date fair value per share $ 7.97 $ 4.60 $ 3.37
Summary of Stock Options	The following is a summary of stock option activity: Number Weighted- Aggregate Intrinsic Balance as of April 24, 2021 2,697 $ 28.31 Granted 290 30.74 Exercised (175) 22.76 Canceled (75) 43.01 Balance as of April 30, 2022 2,737 $ 28.52 $ 15,615 Vested or expected to vest as of April 30, 2022 2,727 $ 28.53 $ 15,557 Exercisable as of April 30, 2022 1,707 $ 30.39 $ 9,858
Summary of Non-Vested Restricted Stock Awards and Performance Unit Awards	The following is a summary of restricted stock award activity: Restricted Stock Awards Shares Weighted- Outstanding at April 24, 2021 54 $ 30.63 Granted 32 31.86 Vested (53) 30.45 Forfeitures (6) 33.29 Outstanding at April 30, 2022 27 $ 31.86 The following is a summary of restricted stock unit activity: Restricted Stock Units Shares Weighted- Outstanding at April 24, 2021 1,241 $ 25.65 Granted 417 30.79 Vested (586) 26.42 Forfeitures (70) 26.92 Outstanding at April 30, 2022 1,002 $ 27.24 The following is a summary of performance unit award activity at target: Performance Unit Awards Shares Weighted- Outstanding at April 24, 2021 288 $ 22.94 Granted 150 29.67 Vested — — Forfeitures and cancellations — — Outstanding at April 30, 2022 438 $ 26.14
Summary of Weighted-Average Assumptions Under ESPP and CAP	We estimate the grant date fair value of shares purchased under our ESPP using the Black-Scholes option pricing valuation model with the following assumptions: Fiscal Year Ended April 30, April 24, April 25, Expected dividend yield 3.6 % 3.6 % 5.1 % Expected stock price volatility 28.6 % 51.7 % 34.3 % Risk-free interest rate 0.3 % 0.1 % 1.6 % Expected life (years) 0.6 0.6 0.6 Weighted average grant date fair value per share $ 6.79 $ 8.77 $ 4.98

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss ("AOCL") (Tables)	12 Months Ended
	Apr. 30, 2022
Equity [Abstract]
Summary of the Changes in Accumulated Other Comprehensive Loss	The following table summarizes the changes in AOCL as of April 30, 2022: Cash Flow Currency Total AOCL at April 24, 2021 $ (4,496) $ (58,096) $ (62,592) Other comprehensive income before reclassifications — (19,966) (19,966) Amounts reclassified from AOCL 1,042 — 1,042 AOCL at April 30, 2022 $ (3,454) $ (78,062) $ (81,516)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended				12 Months Ended
	Apr. 30, 2022 USD ($)	Apr. 24, 2021 USD ($)	Jul. 25, 2020 USD ($)	Apr. 25, 2020 USD ($)	Apr. 30, 2022 USD ($) Segment reportingUnit	Apr. 24, 2021 USD ($)	Apr. 25, 2020 USD ($)
Accounting Policies [Abstract]
Number of reportable segments | Segment					3
Maturity period of maximum (in days)					90 days
Inventories valued at LIFO as % of total inventories	85%	83%			85%	83%
Inventory, LIFO reserve	$ 130,959,000	$ 120,775,000			$ 130,959,000	$ 120,775,000
Property, Plant and Equipment [Line Items]
Number of reporting units | reportingUnit					2
Goodwill impairment	0	0			$ 0	0	$ 675,055,000
Indefinite-lived intangible assets, impairment	0	0		$ 0
Amortization expense					7,267,000	2,346,000	0
Contract assets	134,000	2,491,000			134,000	2,491,000
Contract liabilities	38,581,000	23,526,000			38,581,000	23,526,000
Contract liability, revenue recognized					$ 20,658,000
Liability for percentage of maximum potential amount that could be redeemed					88%
Advertising expense					$ 1,532,000	$ 134,000	$ 5,793,000
Animal Health
Property, Plant and Equipment [Line Items]
Goodwill impairment	$ 269,000,000	$ 675,055,000	$ 406,055,000
Dental
Property, Plant and Equipment [Line Items]
Goodwill impairment				$ 0
Building
Property, Plant and Equipment [Line Items]
Estimated useful lives					39 years
Computer Hardware And Software | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives					3 years
Computer Hardware And Software | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives					10 years
Office Furniture And Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives					5 years
Office Furniture And Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives					10 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Related Party Transactions (Details) - Equity Method - USD ($)	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Related Party Transaction [Line Items]
Purchases	$ 128,452,000	$ 110,210,000	$ 94,238,000
Sales	$ 117,347,000	$ 93,577,000	$ 110,262,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Other Income, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Accounting Policies [Abstract]
Gains on investments	$ 101,809	$ 0	$ 34,334
Gain (loss) on interest rate swap agreements	15,835	1,151	(18,712)
Other	11,896	12,457	7,877
Other income, net	$ 27,731	$ 13,608	$ (10,835)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies -Other Non-current Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Accounting Policies [Abstract]
Investments	$ 139,182	$ 105,522
Development costs of software to be sold, net	64,513	68,156
Other	42,995	21,703
Other non-current assets, net	$ 107,508	$ 89,859

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Accounting Policies [Abstract]
Income tax expense related to cash flow hedge losses	$ 321	$ 321	$ 2,460

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Computation of Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Earnings Per Share [Abstract]
Denominator for basic earnings per share – weighted average shares (in shares)	97,277	95,599	94,154
Effect of dilutive securities – stock options, restricted stock and stock purchase plans (in shares)	1,237	1,065	0
Diluted (in shares)	98,514	96,664	94,154
Antidilutive securities excluded from computation of earnings per share	772	1,014	2,517
Antidilutive securities excluded from computation of earnings per share (in shares)			905

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Jul. 31, 2021	Apr. 30, 2022	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Asset Acquisition [Line Items]
Cash consideration paid			$ 19,793	$ 0	$ 0
Goodwill		$ 140,630	$ 140,630	$ 139,932
Miller Vet Holdings, LLC
Asset Acquisition [Line Items]
Cash consideration paid	$ 19,793
Liabilities assumed	6,799
Total identifiable intangible assets	14,000
Goodwill	1,063
Tangible assets	$ 4,796
Goodwill decrease		$ 66

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Cash and Cash Equivalents [Abstract]
Cash on hand	$ 138,828	$ 141,546
Money market funds	3,186	1,698
Total	142,014	143,244
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	142,014	143,244
Unsettled Financing Arrangements
Cash and Cash Equivalents [Abstract]
Total	39,106	36,771
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 39,106	$ 36,771

Receivables Securitization Pr_3

Receivables Securitization Program (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Maximum available under Purchase Agreement	$ 200,000
Eligible receivables, amount utilized under Purchase Agreement	200,000
Receivables transferred and derecognized, fair value	396,443	$ 384,950
Proceeds from receivables sold	426,188	401,535	$ 346,077
Loss on sale of receivables	(3,247)	(3,338)	(7,242)
Receivables Purchase Agreements
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Trade receivable sold under facility	3,643,700	3,171,456	2,068,409
Proceeds from receivables sold	$ 3,632,145	$ 3,094,060	$ 2,128,394

Receivables Securitization Pr_4

Receivables Securitization Program - Activity in DPP Receivable (Details) - Receivables Purchase Agreements - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 30, 2022	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Beginning DPP receivable balance		$ 183,999	$ 117,327	$ 57,238
Non-cash additions to DPP receivable	$ 1,052,938		768,619	552,751
Cash collections on DPP receivable	(1,041,173)		(701,947)	(492,662)
Ending DPP receivable balance	$ 195,764	$ 195,764	$ 183,999	$ 117,327

Customer Financing (Details)

Customer Financing (Details)	12 Months Ended
	Apr. 30, 2022 USD ($) contract	Apr. 24, 2021 USD ($)	Apr. 25, 2020 USD ($)
Customer Financing [Line Items]
Maximum credit financed for equipment purchases for any one customer	$ 1,000,000
Number of customer financing contracts | contract	2
Financing contracts sold	$ 314,732,000	$ 369,497,000	$ 357,616,000
Net sales from sales of financing contracts	(18,379,000)	(2,048,000)	43,919,000
Proceeds from receivables sold	426,188,000	401,535,000	$ 346,077,000
Cash and cash equivalents	142,014,000	143,244,000
Current receivables of finance contracts not yet sold	58,190,000	50,638,000
Finance contracts receivable sold and outstanding	$ 575,231,000
Maximum bad debt write-offs (percentage)	1%
Unsettled Financing Arrangements
Customer Financing [Line Items]
Cash and cash equivalents	$ 39,106,000	$ 36,771,000
The Bank of Tokyo-Mitsubishi UFJ, Ltd.
Customer Financing [Line Items]
Percentage of principal amount of financing contracts held as collateral (at least)	15%
Capacity under agreement	$ 525,000,000
Fifth Third Bank
Customer Financing [Line Items]
Percentage of principal amount of financing contracts held as collateral (at least)	15%
Capacity under agreement	$ 100,000,000

Customer Financing - Activity i

Customer Financing - Activity in DPP Receivables (Details) - Customer Finance Contracts - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning DPP receivable balance	$ 227,967	$ 228,019	$ 121,657
Non-cash additions to DPP receivable	69,689	131,959	154,644
Cash collections on DPP receivable	(172,324)	(132,011)	(48,282)
Ending DPP receivable balance	$ 125,332	$ 227,967	$ 228,019

Derivative Financial Instrume_3

Derivative Financial Instruments - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2015	Jan. 25, 2020	Jan. 25, 2020	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020	Mar. 25, 2015	Jan. 31, 2014
Derivative [Line Items]
Accelerated amortization of debt issuance costs on early retirement of debt		$ 8,984,000	$ 8,134,000
Gains or losses recognized in OCI on derivatives				$ 0	$ 0	$ 0
Hedge ineffectiveness recorded				0	0	$ 0
Cash flow hedge gain (loss) to be reclassified into earnings over the next twelve months				(1,363,000)
Interest Rate Cap
Derivative [Line Items]
Derivative, notional amount				525,000,000
Interest Rate Cap, Funding II
Derivative [Line Items]
Derivative, notional amount				100,000,000
Interest Rate Swap Agreement
Derivative [Line Items]
Derivative, notional amount				574,144,000	653,122,000			$ 250,000,000
Percentage of senior notes								5.17%
Settlement of swap	$ 29,003,000			6,770,000	$ 9,373,000
Interest Rate Swap Agreement | Senior Notes 3.48%
Derivative [Line Items]
Percentage of senior notes							3.48%
Aggregate principal amount							$ 250,000,000
Interest Rate Swap Two
Derivative [Line Items]
Derivative, notional amount				$ 179,818,000

Derivative Financial Instrume_4

Derivative Financial Instruments - Fair Value of Interest Rate Contracts Included in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Derivatives, Fair Value [Line Items]
Interest rate contracts, assets, fair value	$ 23,746	$ 2,120
Interest rate, liabilities, fair value	10,263	11,571
Interest rate contracts
Derivatives, Fair Value [Line Items]
Interest rate, liabilities, fair value	10,263	11,571
Prepaid Expenses and Other Current Assets | Interest rate contracts
Derivatives, Fair Value [Line Items]
Interest rate contracts, assets, fair value	3,875	0
Other non-current assets | Interest rate contracts
Derivatives, Fair Value [Line Items]
Interest rate contracts, assets, fair value	19,871	2,120
Other accrued liabilities | Interest rate contracts
Derivatives, Fair Value [Line Items]
Interest rate, liabilities, fair value	250	3,776
Other non-current liabilities | Interest rate contracts
Derivatives, Fair Value [Line Items]
Interest rate, liabilities, fair value	$ 10,013	$ 7,795

Derivative Financial Instrume_5

Derivative Financial Instruments - Effect of Interest Rate Contracts and Interest Rate Swaps on Consolidated Statements of Income and Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on interest rate swap agreements	$ 15,835	$ 1,151	$ (18,712)
Interest rate contracts | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified form Accumulated Other Comprehensive Loss	(1,363)	(1,363)	(10,458)
Interest rate contracts | Other income, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on interest rate swap agreements	$ 15,835	$ 1,151	$ (18,712)

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Assets:
Cash equivalents	$ 3,186	$ 1,698
Cash equivalents	195,764	183,999
DPP receivable - customer financing	125,332	227,967
Derivative instruments	23,746	2,120
Total assets	348,028	415,784
Liabilities:
Derivative instruments	10,263	11,571
Level 1
Assets:
Cash equivalents	3,186	1,698
Cash equivalents	0	0
DPP receivable - customer financing	0	0
Derivative instruments	0	0
Total assets	3,186	1,698
Liabilities:
Derivative instruments	0	0
Level 2
Assets:
Cash equivalents	0	0
Cash equivalents	0	0
DPP receivable - customer financing	0	0
Derivative instruments	23,746	2,120
Total assets	23,746	2,120
Liabilities:
Derivative instruments	10,263	11,571
Level 3
Assets:
Cash equivalents	0	0
Cash equivalents	195,764	183,999
DPP receivable - customer financing	125,332	227,967
Derivative instruments	0	0
Total assets	321,096	411,966
Liabilities:
Derivative instruments	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 30, 2022 USD ($)	Apr. 30, 2022 USD ($)	Apr. 24, 2021 USD ($)	Apr. 25, 2020 USD ($) investment
Schedule of Investments [Line Items]
Noncash gain on investment		$ 101,809	$ 0	$ 34,334
Investment				51,628
Gains on investments		101,809	0	$ 34,334
Number of investments | investment				1
Estimated fair value of debt	$ 489,777	489,777	610,811
Long-term debt	488,554	488,554	588,295
Vetsource
Schedule of Investments [Line Items]
Carrying value of investment sold		25,814
Proceeds from sale of investment		56,849
Gain on sale of investment		31,035
Noncash gain on investment		31,035
Investment	56,849	56,849	25,814
Gain on investment put option		25,757
Carrying value of put option	25,757	25,757
Gains on investments		87,827
Vets Plus
Schedule of Investments [Line Items]
Carrying value of investment sold		4,009,000
Proceeds from sale of investment		17,101
Gain on sale of investment	13,092
Investment	$ 2,355	$ 2,355	$ 2,355

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) $ in Thousands	12 Months Ended
	Apr. 30, 2022 USD ($)
Goodwill [Roll Forward]
Beginning Balance	$ 139,932
Acquisition Activity	997
Foreign Currency Translation	(299)
Ending Balance	140,630
Operating Segments | Dental net sales
Goodwill [Roll Forward]
Beginning Balance	139,932
Acquisition Activity	0
Foreign Currency Translation	(299)
Ending Balance	139,633
Operating Segments | Animal Health net sales
Goodwill [Roll Forward]
Beginning Balance	0
Acquisition Activity	997
Foreign Currency Translation	0
Ending Balance	997
Operating Segments | Corporate net sales
Goodwill [Roll Forward]
Beginning Balance	0
Acquisition Activity	0
Foreign Currency Translation	0
Ending Balance	$ 0

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Balances of Other Intangible Assets Excluding Goodwill (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Unamortized - indefinite lived:
Trade name	$ 12,300	$ 12,300
Amortized - definite lived:
Gross	565,722	561,917
Accumulated Amortization	(325,408)	(294,573)
Net	240,314	267,344
Total identifiable intangible assets, gross	578,022	574,217
Total amortized intangible assets	252,614	279,644
Customer relationships
Amortized - definite lived:
Gross	366,969	355,685
Accumulated Amortization	(181,280)	(159,376)
Net	185,689	196,309
Trade names and trademarks
Amortized - definite lived:
Gross	132,996	133,834
Accumulated Amortization	(95,903)	(85,221)
Net	37,093	48,613
Developed technology and other
Amortized - definite lived:
Gross	65,757	72,398
Accumulated Amortization	(48,225)	(49,976)
Net	$ 17,532	$ 22,422

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Additional Information (Details) $ in Thousands	Apr. 30, 2022 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023	$ 37,357
2024	36,699
2025	36,694
2026	26,884
2027	$ 25,491

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Property, Plant and Equipment [Abstract]
Land	$ 11,341	$ 12,014
Buildings	106,957	118,582
Leasehold improvements	31,395	31,125
Furniture and equipment	187,093	188,594
Computer hardware and software	254,205	244,537
Construction-in-progress	30,502	17,665
Property and equipment, gross	621,493	612,517
Accumulated depreciation	(408,353)	(393,079)
Property and equipment, net	213,140	219,438
Unamortized capitalized computer development	$ 8,585	$ 6,326

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	12 Months Ended
	Apr. 30, 2022 USD ($) investment	Apr. 24, 2021 USD ($)
Leases [Abstract]
Options to renew | investment	1
Lease cost | $	$ 35,646	$ 34,712

Leases - Future Maturities of L

Leases - Future Maturities of Lease Liabilities (Details) $ in Thousands	Apr. 30, 2022 USD ($)
Leases [Abstract]
2021	$ 31,165
2022	21,793
2023	12,650
2024	6,168
2025	2,941
After 2025	1,222
Total lease payments	75,939
Less: imputed interest	(3,259)
Operating lease liabilities	$ 72,680

Leases - Supplemental Informati

Leases - Supplemental Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 38,192	$ 37,054
Lease assets obtained in exchange for new operating lease liabilities	$ 31,132	$ 50,114
Weighted-average remaining lease term - operating leases	2 years 11 months 23 days	3 years 21 days
Weighted-average discount rate - operating leases	3.10%	3.31%

Debt - Long-Term Debt (Details)

Debt - Long-Term Debt (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1,946)	$ (2,955)
Total	488,554	588,295
Less: current debt obligations	0	(100,750)
Long-term debt	$ 488,554	487,545
Senior notes due fiscal 2022
Debt Instrument [Line Items]
Fixed rate	3.59%
Fixed rate senior notes	$ 0	100,750
Senior notes due fiscal 2024
Debt Instrument [Line Items]
Fixed rate	3.74%
Fixed rate senior notes	$ 33,000	33,000
Senior notes due fiscal 2025
Debt Instrument [Line Items]
Fixed rate	3.48%
Fixed rate senior notes	$ 117,500	117,500
Senior notes due fiscal 2028
Debt Instrument [Line Items]
Fixed rate	3.79%
Fixed rate senior notes	$ 40,000	40,000
Term Loan due 2024
Debt Instrument [Line Items]
Fixed rate	1.89%
Fixed rate senior notes	$ 300,000	$ 300,000
Term Loan due 2024 | LIBOR
Debt Instrument [Line Items]
Interest rate	1.13%

Debt - Schedule of Debt Maturit

Debt - Schedule of Debt Maturities (Details) $ in Thousands	Apr. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 0
2024	333,000
2025	117,500
2026	0
2027	0
Thereafter	40,000
Total	$ 490,500

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jan. 25, 2020	Jan. 25, 2020	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020	Feb. 16, 2021
Line of Credit Facility [Line Items]
Outstanding debt			$ 490,500,000
Repayment of debt	$ 373,750,000		$ 100,750,000	$ 0	$ 460,840,000
Accelerated amortization of debt issuance costs on early retirement of debt	$ 8,984,000	$ 8,134,000
Amended Credit Agreement | Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity						$ 700,000,000
Outstanding debt						29,000,000
Fixed rate			1.54%
Amended Credit Agreement | Term Loan due February 2024
Line of Credit Facility [Line Items]
Maximum borrowing capacity						$ 300,000,000
Outstanding debt			$ 300,000,000
Fixed rate			1.89%

Income Taxes - Income From Cont

Income Taxes - Income From Continuing Operations Before Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Income Tax Disclosure [Abstract]
United States	$ 225,195	$ 166,251	$ (594,431)
International	41,059	33,680	4,024
Income (loss) before taxes	$ 266,254	$ 199,931	$ (590,407)

Income Taxes - Components of Pr

Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Current:
Federal	$ 46,964	$ 36,836	$ 18,300
Foreign	11,968	9,975	7,501
State	10,326	8,771	4,959
Total current expense	69,258	55,582	30,760
Deferred:
Federal	(3,918)	(7,529)	(25,918)
Foreign	(217)	(362)	164
State	(583)	(2,869)	(6,046)
Total deferred benefit	(4,718)	(10,760)	(31,800)
Income tax expense (benefit)	$ 64,540	$ 44,822	$ (1,040)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Tax Credit Carryforward [Line Items]
Foreign net operating loss carryforwards	$ 18,615
Gross unrecognized tax benefits	9,898	$ 10,866	$ 11,740
Deferred tax assets, deductibility of gross liabilities	1,786	2,055
Interest and penalties	1,583	$ 2,026
Increase in interest and penalties expense	$ 229
Foreign Tax Credit Carryforward
Tax Credit Carryforward [Line Items]
Expiration period	4 years

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Apr. 24, 2021
Deferred tax assets:
Employee compensation and benefits	$ 9,352	$ 12,223
Inventory related items	9,985	12,250
Foreign deferred assets, net	11,812	9,510
Foreign tax credit	7,037	7,112
Lease liability	14,416	16,153
Accrued charitable contributions	6,559	0
Other accrued liabilities	6,642	7,331
Other	5,190	5,372
Gross deferred tax assets	70,993	69,951
Less: Valuation allowance	(18,615)	(15,960)
Total net deferred tax assets	52,378	53,991
Deferred tax liabilities
LIFO reserve	(20,965)	(25,913)
Amortizable intangibles	(52,952)	(61,023)
Goodwill	(15,727)	(13,902)
Property, plant, equipment	(38,175)	(39,454)
Lease right-of-use assets	(14,103)	(15,547)
Investments	(26,449)	(16,353)
Other	(3,401)	(5,590)
Total deferred tax liabilities	(171,772)	(177,782)
Deferred net long-term income tax liability	$ (119,394)	$ (123,791)

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective Income Tax Expense Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Income Tax Disclosure [Abstract]
Tax at U.S. statutory rate	$ 55,912	$ 41,984	$ (123,987)
State tax provision, net of federal benefit	9,176	5,400	(466)
Effect of foreign taxes	3,199	2,594	7,277
Goodwill impairment	0	0	107,999
Legal settlement	0	0	11,088
ESOP	(2,121)	(2,286)	(2,393)
Other permanent differences	944	808	1,533
Other	(2,570)	(3,678)	(2,091)
Income tax expense (benefit)	$ 64,540	$ 44,822	$ (1,040)

Income Taxes - Summary of Chang

Income Taxes - Summary of Changes in Gross Amounts of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of period	$ 10,866	$ 11,740
Additions for tax positions related to the current year	1,001	1,264
Additions for tax positions of prior years	42	20
Reductions for tax positions of prior years	(77)	(220)
Statute expirations	(1,527)	(1,938)
Settlements	(407)	0
Balance at end of period	$ 9,898	$ 10,866

Technology Partner Innovation_2

Technology Partner Innovations, LLC ("TPI") (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020	Apr. 27, 2019
Schedule of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest	$ 1,496	$ 872	$ 921
Noncontrolling interest	959	1,455
Technology Partner Innovations, LLC
Schedule of Equity Method Investments [Line Items]
Net assets contributed	1,000			$ 4,000
Net loss attributable to noncontrolling interest	1,496	$ 872	$ 921
Noncontrolling interest	959
Technology Partner Innovations, LLC | Cure Partners
Schedule of Equity Method Investments [Line Items]
Net assets contributed	$ 1,000

Segment and Geographic Data - A

Segment and Geographic Data - Additional Information (Details)	12 Months Ended
	Apr. 30, 2022 Segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segment and Geographic Data - I

Segment and Geographic Data - Information by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 6,499,405	$ 5,912,066	$ 5,490,011
Property and equipment, net	213,140	219,438
Assets	2,741,630	2,751,511
Dental net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	2,516,132	2,327,021	2,101,922
Assets	851,746	863,718
Animal Health net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	3,982,874	3,559,994	3,336,253
Assets	1,459,450	1,391,892
Corporate net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	399	25,051	51,836
Assets	430,434	495,901
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	5,358,489	4,877,070	4,554,345
Property and equipment, net	200,839	209,361
United States | Dental net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	2,259,579	2,107,521	1,900,539
United States | Animal Health net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	3,098,511	2,744,498	2,601,970
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	717,481	677,910	608,320
Property and equipment, net	6,045	2,471
United Kingdom | Animal Health net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	717,481	677,910	608,320
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	423,435	357,086	327,346
Property and equipment, net	6,256	7,606
Canada | Dental net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	256,553	219,500	201,383
Canada | Animal Health net sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 166,882	$ 137,586	$ 125,963

Segment and Geographic Data - S

Segment and Geographic Data - Sales Information by Product (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Segment Reporting Information [Line Items]
Net sales	$ 6,499,405	$ 5,912,066	$ 5,490,011
Consumable
Segment Reporting Information [Line Items]
Net sales	5,248,040	4,748,416	4,374,829
Equipment and software
Segment Reporting Information [Line Items]
Net sales	920,424	822,063	749,390
Other
Segment Reporting Information [Line Items]
Net sales	330,941	341,587	365,792
Dental net sales
Segment Reporting Information [Line Items]
Net sales	2,516,132	2,327,021	2,101,922
Dental net sales | Consumable
Segment Reporting Information [Line Items]
Net sales	1,424,677	1,314,236	1,141,189
Dental net sales | Equipment and software
Segment Reporting Information [Line Items]
Net sales	800,144	730,928	677,677
Dental net sales | Other
Segment Reporting Information [Line Items]
Net sales	291,311	281,857	283,056
Animal Health net sales
Segment Reporting Information [Line Items]
Net sales	3,982,874	3,559,994	3,336,253
Animal Health net sales | Consumable
Segment Reporting Information [Line Items]
Net sales	3,823,363	3,434,180	3,233,640
Animal Health net sales | Equipment and software
Segment Reporting Information [Line Items]
Net sales	120,280	91,135	71,713
Animal Health net sales | Other
Segment Reporting Information [Line Items]
Net sales	39,231	34,679	30,900
Corporate net sales
Segment Reporting Information [Line Items]
Net sales	399	25,051	51,836
Corporate net sales | Other
Segment Reporting Information [Line Items]
Net sales	$ 399	$ 25,051	$ 51,836

Segment and Geographic Data -_2

Segment and Geographic Data - Information about Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Segment Reporting Information [Line Items]
Operating income (loss)	$ 157,002	$ 210,607	$ (572,119)
Depreciation and amortization	81,992	76,549	82,182
Total assets	2,741,630	2,751,511
Dental net sales
Segment Reporting Information [Line Items]
Operating income (loss)	180,212	201,244	168,304
Depreciation and amortization	13,495	7,774	8,434
Total assets	851,746	863,718
Animal Health net sales
Segment Reporting Information [Line Items]
Operating income (loss)	114,403	88,123	(594,743)
Depreciation and amortization	44,561	45,771	49,958
Total assets	1,459,450	1,391,892
Corporate net sales
Segment Reporting Information [Line Items]
Operating income (loss)	(137,613)	(78,760)	(145,680)
Depreciation and amortization	23,936	23,004	$ 23,790
Total assets	$ 430,434	$ 495,901

Stockholders' Equity - Cash Div

Stockholders' Equity - Cash Dividends Declared and Paid (Details) - $ / shares	3 Months Ended
	Apr. 30, 2022	Jan. 29, 2022	Oct. 30, 2021	Jul. 31, 2021	Apr. 24, 2021	Jan. 23, 2021	Oct. 24, 2020	Jul. 25, 2020	Apr. 25, 2020	Jan. 25, 2020	Oct. 26, 2019	Jul. 27, 2019
Equity [Abstract]
Cash dividend paid (in usd per share)	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26	$ 0.26

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		12 Months Ended
	Sep. 30, 2006	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020	Apr. 25, 2015	Dec. 31, 2002	Mar. 13, 2013	Dec. 31, 1991
Shareholders Equity [Line Items]
common stock repurchased (in shares)		1,032	0	0
Common stock repurchased		$ 35,000
Average cost of common shares repurchased (in usd per share)		$ 33.90
Shares authorized for repurchase under share repurchase program (in shares)							500,000
Remaining shares available under repurchase program (in shares)		465,000
Hours of service completed in order to be allocated shares of stock acquired by plan		1000 hours
Number of shares allocated to ESOP (in shares)		9,551
Number of shares allocated to ESOP, Fair value		$ 293,879
ESOP share based compensation expense		$ 0	$ 9,265	$ 14,419
Thompson Dental Company
Shareholders Equity [Line Items]
Additional loan to ESOP						$ 12,612
ESOP acquiring shares during acquisition (in shares)						666
Interest due from ESOP					$ 200
Total shares allocated to ESOP (in shares)						98
Remaining shares in ESOP (in shares)						568
Committed-to-be-released (in shares)		0
Suspense shares (in shares)		0
1990 Note
Shareholders Equity [Line Items]
ESOP company loan								$ 22,000
2006 Senior Notes
Shareholders Equity [Line Items]
ESOP company loan	$ 105,000
ESOP acquiring shares during acquisition (in shares)	3,160				844
Contributed to ESOP					$ 20,214

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 29, 2018	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense recognized		$ 23,805	$ 21,223	$ 22,935
After-tax stock-based compensation expense		18,686	$ 16,387	17,789
Compensation cost before income taxes related to non-vested awards yet to be recognized		$ 22,718
Total compensation cost expected to be recognized over a weighted average period		1 year 3 months 18 days
Number of shares outstanding (in shares)		2,737,000	2,697,000
Granted (in usd per share)		$ 30.74
Weighted average remaining contractual lives of options outstanding		6 years 9 months 18 days
Weighted average remaining contractual lives of options exercisable		6 years
Stock options exercised, intrinsic value		$ 1,552	$ 953
Stock options exercised, cash received		3,975	3,399
Stock options exercised, tax benefit		$ 238		$ 129
Exercised (in shares)		175,000		0
Inducement Awards | First Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting, percentage		33%
Inducement Awards | Second Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting, percentage		33%
Inducement Awards | Third Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting, percentage		33%
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of performance units vested		586,000
Restricted Stock Units | First Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting, percentage	50%
Restricted Stock Units | Second Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting, percentage	50%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		10 years
Performance Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of performance units vested		0
Chief Executive Officer | Inducement Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in share)	99,000
Granted (in usd per share)	$ 22.67
Expiration period	10 years
Chief Executive Officer | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in share)	31,000
Minimum | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Maximum | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 years
2015 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance (in shares)					19,500,000
Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for awards (in shares)		10,515,000
Prior Equity Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares outstanding (in shares)		307,000
Restricted Stock And Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of restricted stock awards vested in period		$ 19,970	$ 11,672	$ 8,788
Restricted Stock And Restricted Stock Units | First Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock vesting period		3 years
Restricted Stock And Restricted Stock Units | Second Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock vesting period		5 years
Restricted Stock And Restricted Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum restriction period for restricted stock and restricted stock units		1 year
Total Shareholder Return | Performance Unit Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock vesting period		3 years	3 years	3 years
Number of performance units vested		0	4,227,000	0
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance (in shares)		9,000,000
Number of shares available for awards (in shares)		1,387,000
Percentage of fair market value of the common stock		85%

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Weighted-Average Assumptions (Details) - $ / shares	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Director And Employee Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	3.40%	4.40%	4.70%
Expected stock price volatility	38.10%	34.60%	26.80%
Risk-free interest rate	1.10%	0.40%	1.80%
Expected life (years)	6 years	6 years	6 years
Weighted average grant date fair value per share (in usd per share)	$ 7.97	$ 4.60	$ 3.37
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	3.60%	3.60%	5.10%
Expected stock price volatility	28.60%	51.70%	34.30%
Risk-free interest rate	0.30%	0.10%	1.60%
Expected life (years)	7 months 6 days	7 months 6 days	7 months 6 days
Weighted average grant date fair value per share (in usd per share)	$ 6.79	$ 8.77	$ 4.98

Stock-based Compensation - Su_2

Stock-based Compensation - Summary of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 25, 2020
Number of Options
Beginning balance (in shares)	2,697,000
Granted (in shares)	290,000
Exercised (in shares)	(175,000)	0
Canceled (in shares)	(75,000)
Ending balance (in shares)	2,737,000
Vested or expected to vest at end of year (in shares)	2,727,000
Exercisable at end of year (in shares)	1,707,000
Weighted- Average Exercise Price
Beginning balance (in usd per share)	$ 28.31
Granted (in usd per share)	30.74
Exercised (in usd per share)	22.76
Canceled (in usd per share)	43.01
Ending balance (in usd per share)	28.52
Vested or expected to vest at end of year (in usd per share)	28.53
Exercisable at end of year (in usd per share)	$ 30.39
Aggregate Intrinsic Value
Balance at end of year	$ 15,615
Vested or expected to vest at end of year	15,557
Exercisable at end of year	$ 9,858

Stock-based Compensation - Su_3

Stock-based Compensation - Summary of Non-Vested Restricted Stock Awards and Performance Unit Awards (Details) shares in Thousands	12 Months Ended
	Apr. 30, 2022 $ / shares shares
Restricted Stock Awards
Shares
Outstanding, Beginning balance (in shares) | shares	54
Granted (in shares) | shares	32
Vested (in shares) | shares	(53)
Forfeitures and cancellations (in shares) | shares	(6)
Outstanding, Ending balance (in shares) | shares	27
Weighted- Average Grant Date Fair Value
Beginning balance (in usd per share) | $ / shares	$ 30.63
Granted (in usd per share) | $ / shares	31.86
Vested (in usd per share) | $ / shares	30.45
Forfeitures and cancellations (in usd per share) | $ / shares	33.29
Ending balance (in usd per share) | $ / shares	$ 31.86
Restricted Stock Units
Shares
Outstanding, Beginning balance (in shares) | shares	1,241
Granted (in shares) | shares	417
Vested (in shares) | shares	(586)
Forfeitures and cancellations (in shares) | shares	(70)
Outstanding, Ending balance (in shares) | shares	1,002
Weighted- Average Grant Date Fair Value
Beginning balance (in usd per share) | $ / shares	$ 25.65
Granted (in usd per share) | $ / shares	30.79
Vested (in usd per share) | $ / shares	26.42
Forfeitures and cancellations (in usd per share) | $ / shares	26.92
Ending balance (in usd per share) | $ / shares	$ 27.24
Performance Unit Awards
Shares
Outstanding, Beginning balance (in shares) | shares	288
Granted (in shares) | shares	150
Vested (in shares) | shares	0
Forfeitures and cancellations (in shares) | shares	0
Outstanding, Ending balance (in shares) | shares	438
Weighted- Average Grant Date Fair Value
Beginning balance (in usd per share) | $ / shares	$ 22.94
Granted (in usd per share) | $ / shares	29.67
Vested (in usd per share) | $ / shares	0
Forfeitures and cancellations (in usd per share) | $ / shares	0
Ending balance (in usd per share) | $ / shares	$ 26.14

Legal Proceedings Legal (Detail

Legal Proceedings Legal (Details) - Plymouth County Retirement System v. Patterson Companies, Inc., Scott P. Anderson and Ann B. Gugino $ in Thousands		3 Months Ended
	Aug. 27, 2021 USD ($)	Oct. 30, 2021 USD ($)	Jul. 31, 2021 USD ($)	Mar. 28, 2018 case
Loss Contingencies [Line Items]
Pending claims | case				1
Litigation settlement	$ 63,000
Proceeds from insurance settlement	$ 35,000
Litigation liability			$ 63,000
Insurance settlements receivable			27,000
Litigation settlement expense			$ 36,000
Gain on litigation settlement		$ 8,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss ("AOCL") - Summary of Accumulated Other Comprehensive Income (Loss) (Details) $ in Thousands	12 Months Ended
	Apr. 30, 2022 USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 963,216
Ending Balance	1,041,676
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(4,496)
Other comprehensive income before reclassifications	0
Amounts reclassified from AOCL	1,042
Ending Balance	(3,454)
Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(58,096)
Other comprehensive income before reclassifications	(19,966)
Amounts reclassified from AOCL	0
Ending Balance	(78,062)
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(62,592)
Other comprehensive income before reclassifications	(19,966)
Amounts reclassified from AOCL	1,042
Ending Balance	$ (81,516)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss ("AOCL") - Additional Information (Details) $ in Thousands	12 Months Ended
	Apr. 30, 2022 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Increase in interest expense	$ 1,363
Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI, tax	$ 321

Schedule II Valuation and Qua_2

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 24, 2021	Apr. 25, 2020
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 6,138	$ 5,123	$ 6,772
Charged to Costs and Expenses	2,769	2,559	2,008
Charged to Other Accounts	0	0	0
Deductions	2,994	1,544	3,657
Balance at End of Period	5,913	6,138	5,123
LIFO inventory adjustment
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	120,775	99,726	91,342
Charged to Costs and Expenses	10,184	21,049	8,384
Charged to Other Accounts	0	0	0
Deductions	0	0	0
Balance at End of Period	130,959	120,775	99,726
Inventory obsolescence reserve
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	29,629	25,526	10,099
Charged to Costs and Expenses	61,647	45,761	27,405
Charged to Other Accounts	0	0	0
Deductions	69,733	41,658	11,978
Balance at End of Period	21,543	29,629	25,526
Total inventory reserve
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	150,404	125,252	101,441
Charged to Costs and Expenses	71,831	66,810	35,789
Charged to Other Accounts	0	0	0
Deductions	69,733	41,658	11,978
Balance at End of Period	$ 152,502	$ 150,404	$ 125,252